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1 Glossary
A Ampere 
Ab Antibody 
Abs Antibodies 
ADCC Antigen dependent cellular 
cytotoxicity 
Ag Antigen 
APS (NH4)2S2O8 = 
Ammoniumpersulfat 
Basophil Basophil granulocyte 
BSA Bovine serum albumine 
CAPD Continuous ambulatory 
peritoneal dialysis 
CD Cluster of differentiation 
CDC Complement dependent 
cytotoxicity 
CKD Chronic kidney disease 
CRD Chronic renal disease 
CTNK CTNK-cell, cytotoxic natural 
killer cell 
DP Dialysis patient 
EC50 Half maximal effective 
concentration 
EGF Epidermal growth factor 
EGFR Epidermal growth factor 
receptor 
ELISA Enzyme linked immunosorbent 
assay 
et al. et alia 
Eosinophil Eosinophil granulocyte 
Erythrocyte Red blood cell 
ESRD End stage renal disease 
E:T ratio effector : target ratio 
e.g. exempli gratia = for instance = 
z.B. 
Fab Fragment antigen binding 
Fc Fragment crystallizable 
FCS Fetal calf serum 
FcR Fc receptor 
FDA Food and Drug Administration 
GFR Glomerular filtration rate 
GM-CSF Granulocyte-macrophage 
colony-stimulating factor  
H2O Water 
H2Odest Distilled water 
HCl Hydrochloric acid 
HCO3
-  Bicarbonate 
HD Hemodialysis 
HF Hemofiltration 
HI Healthy individual 
HRP Horseraddish peroxidase 
IF Immunofluorescence 
i.e. id est = that is 
IL Interleukin 
Incidence Rate of new cases in a given 
period of time 
Ig Immunoglobulin 
K+ potassium 
K/DOQI Kidney Disease Outcomes 
Quality Initiative 
Leukocyte White blood cell 
M molar 
mAb Monoclonal antibody 
MFI Mean fluorescent intensity 
min minute 
ml milliliter 
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mm millimeter 
Neutrophil Neutrophil granulocyte = PMN 
ng nanogram 
Na+ Sodium 
NaOH Sodium hydroxide 
NaH2PO4 Natriumdihydrogenphosphate 
Na2HPO4 Dinatriumhydrogenphosphate 
n.d. not described 
NIPD Nightly intermitting peritoneal 
dialysis 
NK-cell Natural killer cell 
NKF National kidney foundation 
nl nanoliter 
nm nanometer 
PBMC peripheral blood mononuclear 
cell 
pH Potentia hydrogenii 
PD Peritoneal dialysis 
PMN Polymorph nuclear cell = 
neutrophil 
PO4
3-  Phosphate 
Prevalence Number of affected patients in 
a population at a given time 
RRT Renal replacement therapy 
SDS sodium dodecyl sulfate 
SEM standard error of the mean 
TDS Technical data sheet 
TEMED N,N,N,N-
Tetramethylethylendiamin 
thrombo-
cyte 
Blood platelet 
TNFα Tumor necrosis factor α 
V Volt 
VEGF Vascular endothelial growth 
factor 
W Watt 
µl Microliter 
µM Micromolar 
µm Micrometer 
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2 Introduction 
2.1 Chronic kidney disease 
Chronic kidney disease (=CKD =chronic renal disease =CRD) is the progressive, irreversible 
and substantial loss of renal function over a period of time. Many people suffer from this 
disease, in the US the prevalence of CKD in adults was 13% between 1999 and 2004. There 
are no reliable nationwide statistics on the incidence of the first four stages of CKD in 
Germany. The reasons that lead to CKD are numerous, foremost are typical diseases of 
civilization like diabetes, atherosclerosis and hypertension. In 2006, 32% of the patients 
beginning renal replacement therapy (=RRT, necessary in the final stage of CKD) suffered 
diabetes mellitus type 2 and 24% nephrosclerosis due to hypertension1. 
The definition most commonly used to classify CKD in daily routine is the Kidney Disease 
Outcomes Quality Initiative (K/DOQI) of the American National Kidney Foundation (=NKF, 
Amerikanische Nierenstiftung). Depending on the glomerular filtration rate (GFR) and the 
existence of proteinuria, five stages of CKD can be distinguished: 
1. Slightly diminished kidney function (GFR>89ml/min/1.73m², proteinuria existent) 
2. Mild reduction in GFR (GFR 60-89ml/min/1.73m², proteinuria existent) 
3. Moderate reduction in GFR (GFR 30-59ml/min/1.73m²) 
4. Severe reduction in GFR (GFR 15-29ml/min/1.73m²) 
5. Established renal failure (GFR <15ml/min/1.73m²), RRT necessary 
According to the definitions of the NKF, CKD stage 5 is also called "established chronic kidney 
disease". Other terms for this stage include end-stage renal disease (ESRD), chronic kidney 
failure (CKF), chronic renal failure (CRF) or "terminal renal failure"2. 
In order to survive terminal kidney failure, patients have to undergo renal replacement 
therapy (RRT), a palliative treatment of the disease. In 2006, 91,718 patients were on RRT in 
Germany1. In principle, extracorporeal methods can be distinguished from intracorporeal 
ones. Major RRT methods are kidney transplantation (intracorporeal), peritoneal dialysis 
(intracorporeal), or hemodialysis (extracorporeal). CKD and RRT are, however, associated 
with a sharp increase of patient's mortality foremost due to cardiovascular and other 
complication3. The median 5-year survival rate is < 50%, even lower than that of 
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malignancies in general (55%). In Germany, 52% of the deaths among dialysis patients are 
due to cardiovascular diseases, followed by 18% infections and 10% malignancies4, 5, 6. 
The method offering the best long term outcome in regards of life quality and health of the 
RRT recipients is clearly kidney transplantation. It is, if available, much preferable over the 
dialysis methods, extending patients lives in average 15 years more than dialysis would7. 
When comparing the recipients of kidney transplantation to the patients receiving dialysis, 
McDonald et al. found an initial increase in mortality after the operation during the first 
three months. This risk fell below that of the dialysis group after 6 months and from 12 
months onward after transplantation, the risk of mortality was reduced about 80% in 
transplant recipients over the dialysis group8. In Germany, 2,776 patients received a kidney 
transplant in 2006. However, not every patient fits the criteria required to undergo 
transplantation and even the ones that do fit often have to wait many years for a matching 
transplant organ, since there are much more potential recipients than there are donors. The 
mean waiting time required for a cadaveric kidney transplant in Germany was 40 months in 
20061, so many patients depend on dialysis as a RRT, even if only temporarily. 
2.2 Dialysis 
Dialysis is a method to artificially remove unwanted solutes (=substances dissolved in a fluid) 
or free water from a patient’s blood when the kidneys are unable to perform this task. 
The principle of dialysis is an exchange of solutes by diffusion over a semipermeable 
membrane, a barrier that is penetrable for certain substances like Sodium (Na+) or Potassium 
(K+), while holding back others (protein, cells). This principle was discovered by Thomas 
Graham in the 1850s. There are different types of dialysis methods.  
2.2.1 Hemodialysis  
Hemodialysis (=HD, also haemodialysis) is an extracorporeal method of dialysis where 
patients typically undergo treatment three times a week for about four hours. A shunt, (an 
arteriovenous fistula, usually "cimino"-fistula between a. radialis and v. cephalica) is 
punctured and hooked to a dialysis machine9. To prevent clotting, the blood drained from 
the patient is mixed with an anticoagulant such as heparin, since the thrombocytes would 
quickly coagulate when confronted with the alien plastic surfaces of the dialysis filters. The 
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blood then flows through the dialysis machine, where within the dialysis filter, it encounters 
the dialysis solution on the other side of a semipermeable membrane. Counter current flow 
is used, meaning the blood and the solution flow in opposite directions, achieving higher 
concentration gradients and thus increasing the efficiency of the dialysis. Since the two 
compartments (blood and dialysis solution) have different concentrations of certain solutes 
which are able to penetrate the filter, an exchange of solutes happens. This cleanses the 
blood of unwanted solutes such as K+, PO4
3- (phosphate) or urea, while other solutes such as 
HCO3
- (bicarbonate) can be substituted to the patient’s blood. Free water can be removed 
from the blood by application of hydrostatic pressure, causing free water to move across the 
membrane following the pressure gradient. Hemodialysis was first described 1914 by John 
Abel (Baltimore) in animals10 and 1924 by Georg Haas (Gießen) in humans11. In 1945, 
Wilhelm Kolff (Kampen) managed to save the first patients life with dialysis and proved that 
acute renal failure could be survived using hemodialysis. 
2.2.2 Hemofiltration  
Hemofiltration (=HF, also haemofiltration) is an extracorporeal method similar to 
hemodialysis and is mostly used at intensive care units for acute renal failure, since blood 
pressure and blood volume can be adjusted meticulously. It is a slower, continuous method, 
where no dialysis solution is used, but solutes are removed from the blood by convection 
rather than diffusion (as in HD). A hydrostatic pressure is applied to the blood flowing along 
a filter membrane, driving water and solutes out of the blood while retaining proteins and 
cells. Then, an isotonic replacement fluid is added to the blood to replace the lost fluid. HF is 
not a long-term RRT method. 
2.2.3 Peritoneal dialysis  
Peritoneal Dialysis (=PD) is an intracorporeal method that uses the patient's peritoneum (the 
serous membrane lining the abdominal cavity) as a natural semipermeable membrane. 
Dialysis fluid is inserted in the abdominal cavity through a permanently implanted catheter, 
where it remains at night while the patient sleeps (=nightly intermittent PD, NIPD), or it is 
cycled through the abdominal cavity several times during the day (=continuous ambulatory 
PD, CAPD).  
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Worldwide, HD is far more common than PD (in average 11% PD). Some countries like 
Germany have even lower PD percentages (only 4.8% PD in 2006), while others such as the 
UK or Mexico have up to 75% of their dialysis patients on PD12. 
PD offers some advantages over HD such as the ability to undertake treatment at home, 
being free to move during the day (NIPD) and better PO4
3- clearing. The risks and expenses of 
the PD are comparable to HD, with the primary risk in PD being that of infection of the 
catheter followed by peritonitis. The advantages offered by HD are better control of blood 
pressure, less diet restrictions (severe protein loss in PD, i.e. albumin via the peritoneum) 
and better efficiency in removing wastes from the blood.  
In Germany, 808 dialysis patients per million population (pmp) were recorded in 2006 (in 
total 66,508). By far the largest part was hemodialysis (87.5%) with ambulatory central 
hemodialysis (75.2%) as the major type. Peritoneal dialysis accounted for only 4.8% of all 
dialysis. The incidence of dialysis was 213pmp in 20061. 
Since its introduction in the 1960s, dialysis has allowed many patients to survive with 
diseases which only 60 years ago meant certain death. But despite this enormous scientific 
progress it is important to remember that dialysis is no curative treatment (curing a disease) 
but merely a palliative means to elongate life. Because even if an almost normal life is 
possible with dialysis, the long-term consequences of end stage renal disease requiring 
dialysis are grave.  
2.2.4 Consequences of ESRD and dialysis 
CKD is a state of chronic, low-grade inflammation in which blood cells, most notably platelets 
and leukocytes, are constantly activated13. One explanation for this chronic state of 
inflammation is the increased exposure to lipopolysaccharide (LPS) from bacterial 
membranes in the blood due to uremia-related increase in intestinal permeability14. It has 
been shown that CKD patients have an increased risk to contract bacterial infections like 
pneumonia or die of it15,16. 
In dialysis patients, an additional factor comes into play. The contact of the blood to the 
surfaces of dialysis membranes seems to matter in the inflammation process17. The side-
effects of the interaction between the blood cells and the foreign material of the dialysis 
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membrane have been described as "bioincompatibility", a form of inflammatory response18 
scaled both acute and long-term. The acute inflammatory response is regulated by 
numerous mediators, most notably the pro-inflammatory cytokines interleukin-1β (IL-1β), 
tumor necrosis factor α (TNFα) and IL-6. The latter is mostly secreted from PBMC (peripheral 
blood mononuclear cells) in human blood and is the major cytokine to induce the production 
of acute phase proteins such as C- reactive protein (CRP)19, which in daily routine is most 
commonly used to measure inflammatory status. 
This permanent, long-term inflammation has been shown to massively influence the 
mortality in dialysis patients20. The increased mortality is mostly due to a dramatic rise in 
soft tissue calcification and atherosclerosis among dialysis patients21. Even young patients 
who undergo regular dialysis suffer diseases such as coronary artery disease (CAD) which are 
not usually seen in their age-group among non-CKD patients22. Patients receiving regular 
hemodialysis (hence called DP), in comparison to healthy individuals (hence called HI), show 
a significant cognitive decline23 and have a 10 to 30 times higher cardiovascular mortality24, 
due to accelerated atherosclerosis and CAD,
  and age-related macula degeneration.  
The risk to develop tumors is also increased in dialysis patients25, 26. In a big study by 
Maisonneuve et al., more than 830,000 patients who received dialysis for ESRD were 
observed for an average follow-up of 2.5 years. The risk of dialysis patients to develop 
cancer was increased by 80% (standard incidence rate i.e. the rate of observed to expected 
cancer, SIR 1.8) when dialysis patients of all age groups are observed. The risk was especially 
high in patients under the age of 35, with the relative risk going up more than 300% (SIR 3.7). 
In older patients, the risk was closer to that of the normal population (SIR 1.2), i.e. the 
relative risk gradually diminished with age. The tumor entities with the highest increase in 
risk were malignancies of the genitourinary tract such as bladder (1.5) and kidney (3.6) 
tumors. Thyroid and other endocrine cancers (2.3) and hematopoietic cancers such as 
multiple myeloma (3.5) were also more common than in the healthy population27. 
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2.3 Antibodies 
2.3.1 Structure of antibodies 
Antibodies (=Ab), also called Immunoglobulins (=Ig), are proteins in the blood and other 
body fluids of humans which serve the immune system to defend against foreign particles 
that express certain antigens (=Ag) on their surface such as bacteria or tumor cells. They are 
produced in their soluble form by plasma cells, certain types of leukocytes as a reaction to 
the encounter of foreign antigens. The following picture (figure 1) demonstrates the design 
of an antibody: 
 
 
 
 
Figure 1: Schematic drawing of an antibody 
Antibodies consist of two identical heavy 
chains (dark blue/green, VH and CH) and two 
identical light chains (bright blue/green, VL 
and CL) bound to each other by disulfide 
bonds. The antibody’s subclass (IgA, D, E, G or 
M) is determined by its H-chain, while there 
are two subtypes of L-chain (κ or λ). Every 
type of H-chain can be combined with every 
type of L-chain. One Fc ("fragment 
crystallizable") and two Fab parts ("fragment 
antigen binding") of the antibody can be 
distinguished, the Fab fragments being bound 
to the Fc part via hinge-regions. 
At the end of the Fab are the variable domains 
("V", blue) while the rest of the Fab and the Fc 
make up the constant domains ("C", green). 
The end of the variable domain contains the 
antigen-binding site, which determines the 
epitope (region of the Ag recognized by the 
antibody) the antibody binds to28, 29. 
2.3.2 Antigens 
Antigens (=Ag), which can trigger the production of antibodies and are bound by them, are 
foremost structures on the surface of pathogens like bacteria (such as LPS) or tumor cells. 
The antibody binds to a certain epitope of the antigen and triggers an immune reaction.  
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2.3.3 Antibody subtypes 
There are five different subtypes of antibodies in humans (IgA, D, E, G and M), which differ in 
size, biological properties and location in the body. All of them can be found in the blood, 
while some also function as receptors in the membrane of cells. Table 1 gives an overview 
over antibodies found in humans. 
 
Name Subclasses Molecular form Serum concentration Primary location 
IgG IgG1, 2, 3, 
4 
monomer ~ 12 mg/ml serum 
IgA 
 
IgA1, 2 monomer, dimer ~ 3 mg/ml, 90%monomer, 
10%dimer 
epithelium 
IgM - pentamer ~ 1.5mg/ml serum 
IgD - monomer ~ 30µg/ml serum 
IgE - monomer ~ 0.005µg/ml serum 
Table 1: Immunoglobulin subtypes in humans 
IgG, a monomeric Ig with four subtypes (~70%IgG1, 20%IgG2, 5%IgG3 and 5%IgG4) is the 
antibody most often found in the blood and provides the main immunity against foreign 
pathogens. Since it is the smallest Ig, it is the only one which can pass through the placenta's 
blood/blood barrier to provide passive immunity to the fetus. 
IgA, a dimeric Ig with two subclasses (IgA1 and 2) is secreted on all mucosa tissue such as the 
gastro-intestinal tract, the respiratory tract or the genitourinary tract as well as in various 
body fluids. 
IgM, a pentameric Ig with only one subclass, fights pathogens in the early phase of immune 
reaction before enough IgG can be produced. 
IgE, a monomeric Ig with only one subclass, plays an important role in allergic reactions, as it 
binds allergens and triggers histamine release from mast cells. 
IgD, a monomeric Ig with only one subclass, activates basophilic granulocytes and mast cells. 
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2.3.4 Antibodies as drugs 
Since the idea of antibodies was first established in the 1890s by Paul Ehrlich and others30, 
much research has been conducted in this field. In the 1920s, Antibodies were shown to be a 
type of protein by Heidelberger and Avery31; in the 1940s, a lock-and key theory for 
antibodies was proven by Pauling. In the 1960s, the light chain, the Fab and Fc parts were 
described by Edelman and Porter32. A breakthrough was reached when the first monoclonal 
antibodies (mAbs: antibodies with exactly the same structure, i.e. identical antigen 
specificity) could be produced in 1975. This was achieved by Jerne, Köhler and Milstein 
through the fusing of immortal murine myeloma cells and antibody-producing B-cells, then 
selecting successfully fused cells by selection medium33,34. Monoclonal antibodies were first 
humanized in 1988. Before, the antibodies produced were murine (mouse-antibodies), or 
chimerical (variable region murine, constant region human). They were structurally similar 
but different enough to invoke severe immune reactions. The humanization (mostly human 
antibody except for antigen-determining region) was an important step to reduce allergic 
reaction to the foreign proteins experienced by early recipients of chimerical antibodies, 
thereby increasing antibody tolerance. By using transgenic mice, the production of fully 
human antibodies was eventually achieved in 1991, reducing allergic reactions further35, 36. 
Nowadays, many antibodies are approved as treatment of various diseases, foremost 
malignancies. In 2006, 160 different antibodies were in clinical trials or awaiting approval in 
the US. Antibody drugs are usually well tolerated by patients and offer potent therapeutic 
possibilities in addition to the usual approaches of surgery, radio therapy or chemotherapy. 
2.4 EGFR 
The transformation from normal cells to tumor cells (carcinogenesis) requires several 
alterations on the molecular level. One of these alterations can be an increased expression 
of growth receptors to increase stimuli by growth factors. The ErbB protein family is a group 
of such growth receptors that are found in high levels on the surface of many solid tumors37. 
The proteins are named after their genes, the proto-oncogenes c-erbB-1 to 4, whose 
abbreviation derives from the v-erbB, a viral homolog erythroblastic leukemia oncogene. The 
family of ErbB consists of four members, ErbB-1 (=EGFR, epidermal growth factor receptor 
=HER-1), ErbB-2 (=HER-2/neu), ErbB-3 (=HER-3) and ErbB-4 (=HER-4). ErbB-1, -2 and -4 
Introduction 
9 
possess tyrosine kinases in the intracellular compartment. ErbB-3 can only function via 
dimerization with one of the other ErbB subtypes. 
ErbB are receptors for many ligands associated with cell growth. The most ligands have been 
described for EGFR, including EGF (=epidermal growth factor), TGFα (=transforming growth 
factor), HB-EGF (=heparin-binding EGF-like growth factor), AREG (=amphiregulin) and 
epiregulin, all members of the EGF-family. An over-expression of EGFR has been shown for 
numerous tumors38, including colorectal carcinoma, anal cancer39 or head and neck cancer40. 
When not bound by a ligand, EGFR has been shown to assume a "tethered" confirmation, in 
which the dimerization site is blocked by an amino acid side chain, disabling dimerization41. 
Only after binding of a ligand, the receptors turn towards an "untethered" confirmation, 
allowing the receptors to dimerize into homo- or heterodimers. They then 
autophosphorylize and start a downstream signaling cascade42.  
By the overexpression of EGFR on the cell surface, activating dimers like the strongly 
signaling EGFR/HER2neu heterodimer become more numerous on the cells surface. 
Downstream signaling cascades become stronger activated, leading to heightened cell 
proliferation and angiogenesis43, an inhibition of apoptosis44 and metastasis of tumor cells45. 
In a therapeutic approach, monoclonal antibodies (=mAbs) are directed against the 
extracellular domain of the EGFR. Binding of the EGFR by monoclonal antibodies suppresses 
ligand binding and prevents dimerization, thus inhibiting intracellular signaling, resulting in 
halted proliferation and induction of apoptosis46. Apart from these direct effector 
mechanisms, there are also indirect ones (see 2.6.2 below). Antibodies directed against EGFR 
currently approved for clinical application are cetuximab (in Europe marketed by Merck as 
Erbitux®) and panitumumab (marketed by Amgen as Vectibix®). They are both approved for 
the treatment of metastatic colorectal cancer; cetuximab is also approved for the treatment 
of squamous cell carcinoma of the head and neck. Several other monoclonal antibodies 
directed against EGFR are in clinical testing and awaiting FDA approval, e.g. nimotuzumab 
(YM Biosciences, Habana), zalutumumab (Genmab, Utrecht) or necitumumab47. 
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2.5 Fc receptors  
Fc receptors (=FcR) are proteins on cell surfaces that recognize the Fc part of an antibody. 
They play an important role in immune response and can be found on the surface of almost 
all cell types of the immune system48 except possibly on T-cells. There are several types of 
FcR in humans, classified by the types of antibodies they recognize. FcαR, FcγR, FcδR, FcεR 
and FcμR bind IgA, IgG, IgD, IgE and IgM, respectively. 
2.5.1 FcγR 
FcγR, the most important group of the FcR for inducing phagocytosis49, can be divided 
further into subclasses. They differ in their molecular structures and their IgG affinity. The 
following table gives an overview over the FcγR subclass: 
Name CD Affinity Signaling motif Cellular distribution 
FcγRI 64 high γ-chain ITAM Macrophages, monocytes, immature 
neutrophils 
FcγRIIa 32 low α-chain ITAM Macrophages, monocytes, neutrophils, 
platelets, Langerhans cells 
FcγRIIb 32 low α-chain ITIM Macrophages, monocytes, B-cells 
FcγRIIc 32 low α-chain ITAM Macrophages, monocytes, neutrophils,          
B-cells 
FcγRIIIa 16a medium γ-chain ITAM Macrophages, monocytes, NK-cells, γδ T-cells 
FcγRIIIb 16b low GPI-linked receptor Neutrophils (exclusively) 
Table 2: FcγR subclasses 
FcγR are expressed on almost all leukocytic cells such as NK-cells, monocytes, macrophages, 
dendritic cells, neutrophils, basophils or mast cells. They bind the Fc part of IgG and are 
important in determining the leukocyte's response to antibodies in the serum. They belong 
to the large immunoglobulin superfamily (IgSF), a group of proteins involved in cell binding 
and adhesion that is based on shared structural similarity with Igs (=antibodies). All FcγR 
have an extracellular ligand-binding α-chain, a transmembrane region and an intracellular 
domain; only FcγRIIIb is composed slightly different with a GPI-linked receptor. FcγRI and 
FcγRIIIa also have an intracellular γ-chain dimer carrying ITAMs (immunoreceptor tyrosine 
based activating motifs), while the other activating FcγR have the ITAM on their α-chain. 
FcγRIIb, the only inhibitory FcγR, expresses an ITIM (immunoreceptor tyrosine based 
inhibitory motif) on its α-chain. FcγRIIIb, which is exclusively expressed on neutrophils, is a 
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glycosyl-phosphatidylinositol (GPI)-linked receptor. FcγRI is the only high affinity receptor 
with an affinity up to 1000 fold that of the other receptors, leading to a constant saturation 
of FcγRI with ligands. However, activation of this receptor only occurs after the receptors 
have been crosslinked by antigen. The lower affinity of the other FcγRs prevents the binding 
of Ig which are always present in the serum and thus avoids uncontrolled activation of the 
receptors50. FcγRIIb, with its unique inhibitory abilities, plays a critical role in restricting B-cell 
activation. Auto-reactive B-cells constantly arise due to random recombination of 
immunoglobulin loci, which generates B-cell diversity. By restricting their activation via 
FcγRIIb, B-cell tolerance can be maintained and autoinflammation prevented51. 
2.6 Antibodies' mechanism of action 
When regarding the mode of operation of antibodies, direct and indirect effector 
mechanisms can be distinguished, both of which contribute to the abatement of tumor cells 
in vivo.  
2.6.1 Direct effector mechanisms 
The direct effector mechanisms, mediated by the Fab part of the antibody, include the 
inhibition of ligand binding to the receptor (e.g. EGF or TGFα for EGFR), inhibition of receptor 
dimerization or phosphorylation, downregulation of the receptor or induction of apoptosis 
in target cells. The induction of direct effector mechanisms by antibodies is followed by 
regressing in tumor growth52. Since only the antibody is required to induce these effects, 
they depend solely on the properties of the target cell and the antibody. 
2.6.2 Indirect effector mechanisms 
The indirect effector mechanisms, mediated by the Fc part of the antibody, include ADCC, 
CDC and phagocytosis. The antibody binds its antigen with the Fab part, while its Fc part 
interacts with effector cells (leukocytes) or complement factors. 
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2.6.2.1 ADCC 
In ADCC (antibody dependent cellular cytotoxicity), antibodies mediate the lysis of tumor 
cells (=targets) through the interaction with effector cells53 (e.g. NK cells, neutrophils (=PMN) 
or monocytes) (see figure 2).  
 
A target cell (tumor cell) expresses an antigen such as EGFR on its surface, which is bound by the 
Fab part of an antibody such as cetuximab. The antibodies Fc part is bound by the FcR of an effector 
cell such as NK-cells, monocytes or neutrophils (PMN). The binding of the antibody to the FcR 
triggers degranulation of granulae in the effector cells, liberating perforines, granzymes and other 
substances which lead to cell lysis of the target cell. 
2.6.2.2 CDC 
CDC (complement dependent cytotoxicity) mediates the lysis of tumor cells through the 
activation of complement factors, soluble proteins synthesized mostly in liver hepatocytes, 
but also in leukocytes or epithelial cells. Since CDC is not influenced by effector cells, it was 
not tested in these experiments. 
 
 
 
Figure 2: Schematic principle of ADCC:  
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2.6.3 Phagocytosis 
Phagocytosis (greek phago="eating", kytos="cell", osis="process"), a special form of 
endocytosis, is the ingestion of solid particles of subcellular size by scavenger cells 
(phagocytes) such as neutrophils or macrophages. The phagocytes recognize the Fc part of 
the antibody that binds the antigen on the particles surface with its Fab, engulf the particle 
in spurs of the membrane and internalize them in phagosomes. These phagosomes fuse 
with lysosomes, intracellular vesicles with low pH, to form phagolysosomes and digest the 
particle.  
 
A phagocyte (green), such as a neutrophil, monocyte or macrophage, binds a foreign particle 
antibody-mediated (A). It engulfs the particle in membrane spurs (B), internalizing it into a 
phagosome (C). It then fuses the lysosomes (yellow) with the phagosome into a phagolysosome 
(D), digesting the particle. 
 
 
Figure 3: Schematic principle of Phagocytosis:  
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2.6.4 Leukocyte subpopulations 
The indirect effector mechanisms are influenced not only by the properties of the target 
cell and the antibody, but in case of ADCC and phagocytosis, also of the effector cells 
(leukocytes). The leukocytes are influenced constantly by a number of cytokines and 
surface molecules they interact with. The leukocytes are not one homogenous group but 
consist of numerous subgroups (see figure 4), which react differently on these impulses. In 
hemodialysis patients, the leukocytes are regularly in close contact to the plastic 
membrane of the dialysis filters, surfaces with entirely foreign molecules. This can be 
assumed to lead to changes in leukocyte composition and activation status. 
 
 
 
Human blood consists of about 45% 
erythrocytes ("red blood cells", red in A), 
55% plasma (yellow in A) and less than 1% 
of leukocytes ("white blood cells", white in 
A). The leukocytes (shown magnified in B) 
can be subdivided into 60% neutrophilic 
granulocytes ("neutrophils"), 30% 
lymphocytes (consisting mostly of NK-, T- 
and B-cells), 6% monocytes, 3% 
eosinophilic granulocytes ("eosinophils") 
and 1% basophilic granulocytes 
("basophils"). 
 
 
  
2.7 Purpose of the study: 
ESRD patients undergoing regular hemodialysis (=DP) have a permanently activated immune 
system and are in a constant state on low-grade inflammation. The uremic solutes in the 
blood and the constant encounter of foreign surfaces influence the blood's leukocytes and 
change their state of activation. While the body immediately answers these pro-
inflammatory impulses with an activation of the immune system, the impulses seem to 
reduce the immune status when given continually over a long period of time, as in patients 
Figure 4: Composition of human blood. 
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receiving regular hemodialysis. This is indicated by their increase in bacterial infection and 
tumor incidence.  
There is yet little data on how uremia and hemodialysis influence the leukocyte's abilities to 
fend off tumor cells via ADCC or phagocytosis. Treatment with monoclonal antibodies is a 
relatively recent therapeutic option that has seen a dramatic increase in usage in the last 
decade as more and more antibody-drugs are approved, and will certainly become even 
more important in the future. Therefore, knowing whether or not dialysis patients profit 
from the usually cost-intensive antibody-drugs in the same way that healthy individuals (=HI, 
individuals without ESRD, not on dialysis) do is immediately important for clinical decisions. 
Interestingly, two contrary hypotheses can be formulated. While one could argue for 
decreased abilities of leukocytes to fend off tumor cells in vivo via ADCC due to the increased 
tumor incidence found in DP, one could also argue for an increased ability due to the 
permanent state of low-grade inflammation and the constant impulse of pro-inflammatory 
cytokines.  
The data available on whether the ADCC capacity is different in DP from HI is very limited, 
old and somewhat contradicting. In 1981, Badger at al. did a series of experiments on ADCC 
with blood from 23 DP. They found equal or increased lysis rates in ADCC in most of the 
DP54. Also in 1981, Lang et al. showed reduced lysis rates in ADCC among 15 DP55. Both 
groups investigated solely mononuclear cells as effector cell population. To our knowledge, 
no data on neutrophil's ADCC capacity were reported. These two contradicting studies have 
insufficiently explained how ESRD and/or hemodialysis alters ADCC capacity. Further efforts 
are necessary to clarify these questions. 
If a difference in the abilities of DP's leukocytes to fight against tumor cells using antibodies 
can be proposed, be it increased or decreased, then differences in FcγR expression are a 
plausible reason for it. FcγR are the receptors for IgG antibodies and play a vital role in the 
intracellular downstream signaling after encountering foreign antigens. A change in FcγR 
expression among certain leukocytes subpopulations could therefore be proposed. One 
paper from 2002 by Kawanaka et al. showed increased CD16 (FcγRIII) on monocytes from 
DP56. No data has yet been published on the other types of FcγR, or on expression on 
different leukocyte subpopulations from DP such as monocytes or PMN. In a study from 
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2004, Bouts et al. investigated FcR expression of lymphocytes, monocytes and neutrophils, 
and showed significantly reduced levels of FcγRII on all three populations57. Unfortunately, 
this was only investigated in uremic children. Another deficiency in this study was the 
presentation of the results. For FcR quantification, only the measured mean fluorescent 
intensity (MFI) was shown, in oppose to presenting the actual number of molecules on the 
cells surface. No reference particles with defined antigen density (as in Dako's Qifikit) were 
entrained, only the cells labeled with fluorescent antibody were measured using flow 
cytometry. Since the MFI varies from assay to assay, this method is less reliable than the 
direct quantification where an actual number is calculated each day from reference particles 
with defined antigen density. 
In a study from 1996 by Carcamo et al reduced expression of FcγRI and FcγRIII could be 
shown58, but only on peritoneal macrophages and only in patients undergoing peritoneal 
dialysis. Once again, further investigation is necessary to clarify the question of FcR 
expression alteration in DP. 
Apart from ADCC, phagocytosis is the second major form of indirect effector mechanism of 
antibodies. It plays an important role in the body's fight to fend off alien particles like 
bacteria or tumor cells. In order to contribute data to the question whether dialysis 
influences the leukocyte's ability for phagocytosis, a methodical problem had to be solved. 
There is no easily conductible experimental assay that allows measurement of antibody-
dependent phagocytosis of particles coated with EGFR as an antigen.  
The questions and goals of this study are therefore: 
 Are antibody-drugs as effectively mediating ADCC and phagocytosis in DP as in HI?  
 If there are differences between DP and HI, what are possible causes? 
 Does the expression of FcR differ in DP from HI? 
 Establishing an assay for antibody-dependent phagocytosis of EGFR coated 
microspheres 
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3 Methods 
3.1 Study population and consent 
Written informed consent was obtained from fifteen dialysis patients undergoing regular 
hemodialysis (DP) in the department of internal medicine at the University Hospital 
Schleswig-Holstein in Kiel, Germany. Written informed consent was also obtained from 
fifteen healthy individuals (HI). The study protocol was approved by the hospital ethics 
committee before the start of the study. 
3.1.1 Taking of blood samples 
After written informed consent was obtained, blood was taken from DP immediately prior to 
the connection of the dialysis machine. 
Blood was taken from HI by disinfection of the skin (Kodan Hautantiseptikum, Schülke), 
puncturing a venous blood vessel at the arm. The blood was collected into a 10ml tube 
(Monovette-Kanüle, Sarstedt) which included citrate as an anticoagulant and was inverted 
several times. 
Up to 30ml of blood was taken from dialysis patients, up to 100ml from healthy individuals.  
3.2 Cell biological methods 
All cell biological experiments using cell cultures were performed under sterile conditions 
under a sterile lamina airflow workbench (HeraSafe). Only sterile materials, buffers and 
media were used. 
3.2.1 Cell Culture 
Adherent cells (A1207, A431) were prepared two times a week. Medium in the cell culture 
flask was decanted, cells were washed twice with 10ml PBS, then incubated with 1 ml pre-
warmed Trypsin-EDTA solution (0.25%) at 37°C for several minutes, detaching them of the 
flasks plastic wall. Detached cells were decanted into 20ml pre-warmed medium, stopping 
the Trypsin's enzymatic reaction. 1ml of this solution was diluted 1:20 by adding 19ml of new 
medium and returned to a new flask. Cell culture flasks were stored at 37°C and 5% CO2. 
Contamination with Mycoplasma bacteria was controlled monthly by Lonza Kit. 
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3.2.2 Vitality testing, cell count 
Cells were dyed with trypan blue and diluted as required. For a 1:10 dilution, 10µl cell 
suspension was added to 90µl of trypan blue, dispersed, added to a counting chamber 
(Neubauer-Zählkammer, VWR) and viewed through a microscope. Avital cells were dyed 
blue, vital cells remained white. 
Cells in the 4 x 4 Squares of the counting chamber were counted, the number of cells was 
calculated using the following formula: cells/ml = counted cells in 4 squares / (4 x dilution 
factor x 10.000). 
3.2.3 Isolation of Leukocyte -Subpopulations 
 
Percoll gradients of two different densities (63% 
and 70% percoll) are carefully layered atop one 
another. Blood is layered on top (A) and the 
whole tube is centrifuged at 2500min-1 for 20min. 
This results in a separation of the blood's 
components according to their density (B): 
beneath the low-density plasma is the “buffy 
coat” containing the PBMC. The PMN are mainly 
in the layer between the percoll and the 
erythrocytes. 
3.2.3.1 PBMC, PMN by density gradient 
A density gradient consisting of 3ml of two different percoll layers (70%, then 63%) was 
layered briefly with 10ml citrate-anticoagulated blood in a 15ml tube. After centrifugation 
(2500min-1, 20min, no break) the blood's components were separated according to their 
density (see Figure 5). 
The PBMC ("buffy coat") were collected from the plasma/percoll interface, PMN 
(neutrophils) were collected from beneath the percoll layer. The PBMC were placed in a new 
50ml tube, washed with PBS and poured through a strainer with pores of 30µm size to 
remove clotted cells. The remaining erythrocytes were then removed by hypotonic lysis. For 
this, PBMC were filled up to 50ml with PBS, centrifuged (1800min-1, 5min), the pellet 
consequently resuspended in 45ml of 4°C cold distilled water and inverted several times. 
Figure 5: Isolation of PBMC, PMN. 
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After 30 seconds, 5ml of 10xPBS were applied to restore the concentration of the 1xPBS 
phosphate buffer and again the tube was inverted several times. Since the erythrocytes are 
less stable to the osmotic stress than the leukocytes, the erythrocytes were lysed while the 
leukocytes survived. 
The PMN were also placed in a new 50ml tube, washed with PBS (1800min-1, 5min, no break) 
and exposed to hypotonic lysis twice, since many more erythrocytes are mixed in the PMN 
layer than in the PBMC layer. 
PBMC and PMN were counted in a counting chamber and tested for vitality via trypan blue 
exclusion. Their purity was tested by FSC/SSC in flow cytometry. Both were higher than 95%. 
Subsequently, PBMC and PMN were counted and their concentration adjusted to the desired 
level in R10+ medium. 
3.2.3.2 NK-Cells untouched by NK Cell Isolation Kit (Miltenyi Biotec) 
PBMCs were isolated, counted and adjusted to the desired cell number. After centrifugation 
(10min, 2000min-1), the pellet was resuspended in 40µl MACS-Buffer/107 cells.  
10µl „NK Cell Biotin-Antibody Cocktail“/107 cells was added, then incubated for 10min at 
4°C. Subsequently, 30µl MACS-Buffer/107 cells were added, then 20µl „NK Cell Microbead 
Cocktail“/107 cells and incubated anew for 15min at 4°C.  Thereafter, 1-2ml MACS-Buffer/107 
cells was added, centrifuged (10min, 2000min-1) and the pellet resuspended in 500µl MACS-
Buffer. 
An LS-Separation Column was placed in a strong magnetic field of a suitable MACS Separator 
and rinsed with 3ml MACS-Buffer. The cell suspension was added and washed three times 
with 3 ml MACS-Buffer. The collected effluent represented the enriched NK-cell fraction, 
which was subsequently counted and adjusted to the desired concentration. 
3.2.3.3 Monocytes touched by CD14 Microbeads (Miltenyi Biotec) 
PBMCs were isolated, counted and adjusted to the desired cell number. After centrifugation 
(10min, 2000min-1), the pellet was resuspended in 40µl MACS-Buffer/107 cells.  
20µl „CD14 MicroBeads“/107 cells was added, then incubated for 15min at 4°C. 
Subsequently, 1-2ml MACS-Buffer/107 cells was added, centrifuged (10min, 2000min-1) and 
the pellet resuspended in 500µl MACS-Buffer. 
An LS-Separation Column was placed in a strong magnetic field of a suitable MACS Separator 
and rinsed with 3ml MACS-Buffer. The cell suspension was added and washed three times 
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with 3 ml MACS-Buffer. The collected effluent represented the CD14 negative cell fraction. 
The column was removed from the magnetic field and placed atop a new tube. 5ml of 
MACS-Buffer were added and the plunger was pushed firmly into the column, washing out 
the labeled CD14+ cells, which were subsequently counted and adjusted to the desired 
concentration. 
3.2.3.4 Monocytes untouched by Monocyte Isolation Kit II (Miltenyi Biotec) 
PBMCs were isolated, counted and adjusted to the desired cell number. After centrifugation 
(10min, 2000min-1), the pellet was resuspended in 40µl MACS-Buffer/107 cells.  
10µl „Fcγ-Blocking Reagent“/107 cells and 10µl „Biotin-Antibody-Cocktail“/107  cells were 
added, respectively, then incubated for 10 min at 4°C. Subsequently, 30µl MACS-Buffer/107 
cells were added, then 20µl „Anti-Biotin Microbeads“/107 cells and incubated anew for 
15min at 4°C.  Thereafter, 1-2ml MACS-Buffer/107 cells was added, centrifuged (10min, 
2000min-1) and the pellet resuspended in 500µl MACS-Buffer. 
An LS-Separation Column was placed in a strong magnetic field of a suitable MACS Separator 
and rinsed with 3ml MACS-Buffer. The cell suspension was added and washed three times 
with 3 ml MACS-Buffer. The collected effluent represented the enriched monocyte cell 
fraction, which was subsequently counted and adjusted to the desired concentration. 
3.2.4 Fluorescence microscopy 
In order to visualize the phagocytosis of microspheres by PMN, the beads were incubated at 
37°C with different concentrations of PMN over different periods of time. Subsequently, 
cells were washed twice by 100µl of FACS-Buffer, then applied to a glass slide and viewed 
under a fluorescent microscope (Zeiss Imager Z1). If the samples were irradiated by laser 
light (Zeiss ApoTome), the beads fluoresced.  
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3.2.5 Flow Cytometry 
3.2.5.1 Immunofluorescence theory 
Direct (primary) and indirect (secondary) immunofluorescence (IF) can be distinguished; 
both can be measured using a flow cytometer.  
Particles are sped through a capillary at high velocity, passing through a beam of laser light 
of a certain wavelength. Each particle passing through this beam scatters the light, and 
fluorescent parts of the particle (fluorophores) may be exited into emitting light of different 
wavelengths. The light is measured by several detectors, the FSC (forward scatter) which 
changes according to the particle’s volume and the SSC (sidewards scatter) which changes 
according to the particle’s granularity. 
For the direct immunofluorescence (see figure 6), a fluorescently marked antibody, directed 
against an antigen at the particles cell surface, is applied, e.g. a PC-7 labeled antibody against 
human CD56 on the surface of NK-cells. The antibody binds the antigen and can then be 
detected through flow cytometry. 
 
 
 
 
 
An antibody binds to an antigen with its Fab part. 
Its Fc part is marked by a fluorophore, allowing 
its detection in flow cytometry. 
 
 
 
 
Figure 6: Direct immunofluorescence. 
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For the indirect immunofluorescence (see figure 7), an unmarked primary antibody is added, 
binding to the Ag with its Fab part. Subsequently, a fluorescently marked secondary 
antibody, directed against the Fc-part of the primary antibody is added and binds its target, 
the primary antibody, allowing the particle to be detected through flow cytometry. 
 
An antibody binds to an antigen with its Fab part. 
Its Fc part is consequently bound by a secondary 
antibody, which is marked at its Fc part with a 
fluorophore, allowing its detection in flow 
cytometry. 
 
Direct IF is faster and has less background-signals, while indirect IF can be cheaper, as many 
primary antibodies can be marked by a single secondary antibody, avoiding the necessity to 
fluorescently mark each primary antibody individually. 
There are many different fluorophores, the ones used here are the following: 
 
name emission wavelength (nm) 
FITC 519 
PE 578 
ECD 615 
PC-5 670 
PC-7 767 
Table 3: Fluorophores used in immunofluorescence 
 
 
 
Figure 7: Indirect immunofluorescence. 
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3.2.5.2 Assay procedures 
The Qifikit assay should serve as an example for similar assays. 0.5 x 106 cells/well were 
applied to a 96-well V-Bottom microplate and centrifuged (2000min-1, 2min). Fc receptors 
(FcR) were blocked by adding 5µl/well Polyglobin (10mg/ml) per well, saturating the binding 
capacity of the FcR by unspecific human IgGs. 5µl of the primary antibodies (200µg/ml) were 
added /well, which could now only bind to the FcR with their Fab- parts. After incubation for 
15min at 4°C, cells were washed two times by 100µl Facs-Buffer/well. At the indirect IF, the 
secondary antibody was now applied (5µl of the 200µg/ml concentration), incubated for 
30min at 4°C and washed twice again by 100µl Facs-Buffer/well. The cell pellet was then 
resuspended in 100µl PBS, placed in a tube containing 400µl of PBS and measured in a flow 
cytometer. 
The following other flow cytometry assays were performed: 
Assay Antigen 
(Target) 
Primary antibody Secondary antibody Incuba-
tion time 
Without immunofluorescence  
Control of the 
PBMC/PMN-
purification 
- - - - 
Direct immunofluorescence  
Control of NK-cell 
and monocyte 
purification 
human CD 
14, 16, 56 
Isotype controls: IgG -FITC, 
-PE, -PC5 
measuring antibodies: 
CD14-FITC, CD16-PC5, 
CD56-PE 
- 15min at 
4°C 
Composition of 
PBMC: NK-cells, 
monocytes, T- 
and B-cells, CTNK-
cell  
human CD 3, 
16, 19, 32, 
56, 64 
Isotype controls: IgG -FITC, 
-PE, -ECD, -PC5, -PC7 
measuring antibodies: 
CD45-FITC, CD16-PC5, 
CD56-PE 
- 15min at 
4°C 
Indirect immunofluorescence  
Qifikit FcR mTib92, mTH69, mW6/32, 
m22, mIV.3, m3G8, mA77 
gαm IgG FITC 15min at 
4°C 
Binding of EGFR- 
antibodies to 
EGFR-coupled  
beads 
EGFR on 
coupled 
beads 
IgG1, Rituximab, 
Herceptin, 2F8T, 2F8T-Fab, 
IgG2, cetuximab, hR3, 
panitumumab, 003, 005, 
018, h425, IgA2 
gαh IgG-PerCP 
(Jackson 
ImmunoResearch 
Laboratories, Inc.) 
diluted 1:20 
45min at 
4°C 
Table 4: Flow cytometry assays 
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The measured MFI (mean fluorescent intensities) for the 5 peaks of the 5 different beads 
populations (X axis) are shown as points against the antibodies per bead population (as specified by 
the producer). A calibration curve is laid to best fit the 5 points. Calibration curve graph is overlaid 
with flow cytometry data of the calibration beads to visualize the process. 
3.2.5.3 Qifikit 
The Qifikit sold by Dako allows a reliable quantitative determination of surface antigen on 
cells by flow cytometry using indirect immunofluorescence (IF). Cells are labeled with a 
murine primary antibody against the Ag of interest (here: FcR), while other cells are labeled 
with an unspecific mouse antibody as control. Subsequently, cells, setup beads and 
calibration beads from the kit are labeled with the same secondary FITC-labeled anti-mouse 
antibody (gαm-FITC). All antibodies are used at saturating concentration. The calibration 
beads provided by the kit are then used to construct a calibration curve. There are five 
different populations of calibration beads, each with a different amount of antigen on its 
surface. More antigen results in more secondary antibody binding to the beads, yielding a 
higher MFI (mean fluorescent intensity, a measure for the level of fluorescence) in the flow 
cytometry. Therefore, a calibration curve can be constructed by assigning the MFI to the X-
axis and the number of antigens on the surface to the Y-axis. 
By measuring the MFI of the cells analyzed, one can then calculate the antigen density on 
the cell surface according to the manufacturer’s formula. 
Figure 8: Qifikit calibration beads used to set up a calibration curve. 
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3.3 Biochemical methods 
3.3.1 ADCC 
The desired subpopulations of leukocytes, called effectors (PBMC, PMN, monocytes) were 
first purified (see above) and applied in triplets (to reduce variability) to the wells of a 96-
well roundbottom plate. 0.4 x 106 (PMN/PBMC) or 0.2 x 106 (monocytes) effectors were 
applied per well, the antibodies had a concentration of 2µg/ml in the final volume of 200µl 
(less if dilution was used to measure different concentrations). 
Of the targets (“target cells” = A1207, A431), which expressed EGFR on their surface, 0.6 x 
106 per plate were transferred to a 15ml tube and incubated with 100µl  51Cr per 1.2 x 106  
cells for 2h at 37°C, 5% CO2. 
Subsequently, the targets were washed three times with medium and adjusted to a 
concentration of 105 /ml. 5000 targets were added per well, yielding a final E:T-ratio (ratio of 
effectors vs. targets) of 80:1 (PMN, PBMC) or 40:1 (monocytes) and a final volume of 
200µl/well. After further incubation for 3h at 37°C, 5% CO2, cells were centrifuged (2000min
-
1, 5min) and 25µl of the supernatant were carefully transferred to 150µl of a scintillation 
fluid (“Szintillationsflüssigkeit”). This solution was shaken 15min by an orbital shaker and the 
51Cr released by the lysis of the target cells was then measured in a scintillation analyzer 
(MicroTriLux, PerkinElmer). 
The lysis rate of each triplet of wells was calculated using the following formula: 
Lysis = (wellsci-BRsci)*100/(MRsci-BRsci) 
where wellsci was the mean of the scintillation measured in a triplet of wells, BRsci was the 
scintillation of the basal release triplet (no cells, no antibodies) and MRsci was the 
scintillation measured in the maximal release triplet (targets incubated in 2% TritonX, 
yielding a complete lysis). 
The specific lysis rate was then calculated by dividing the lysis rate for each triplet where 
antibody and effectors were combined, by the lysis rate of the triplets in which the effectors 
were incubated without antibody. 
3.3.2 Westernblot 
The Westernblot technique was used to analyze proteins by their molecular weight, for 
example to verify the content of ordered protein solutions like EGFR before coupling it on 
microspheres. It uses gel electrophoresis, in which a voltage is applied to a polyacrylamide 
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gel containing the protein soluted in buffers. After application of a strong denaturing reagent 
(sodium dodecyl sulfate, SDS), the tertiary structure of the protein is lost and is becomes 
covered in the negatively charges SDS. When voltage is applied, the negatively charged 
proteins migrate towards the positively charged electrode through the mesh of the 
acrylamid gel. Smaller proteins migrate faster, thus sorting the proteins by size. Size can be 
determined by comparing the analyzed protein to standards with known molecular weight. 
10ml of a Polyacrylamid gel was prepared by combining 4ml H2Odest, 3.3ml Acrylamid, 2.5ml 
Tris-buffer, 100µl SDS, 100µl APS and 4µl TEMED, the latter serving as catalyst for the 
polymerization. Protein samples were loaded into the prepared wells in the gel with 
Laemmli-buffer. Separation was achieved by applying 135V, 3A, 300W for about 90min. 
Proteins were then transferred to a nitrocellulose membrane. For this, the membrane was 
placed atop the gel, covered in turn by a stack of filter paper. Buffer solution is applied to the 
entire stack, moving up the papers by capillary force and transferring the protein from the 
gel to the membrane. Subsequently, proteins were detected by a primary antibody and the 
latter marked by a HRP-marked secondary antibody. The enzyme produced luminescence in 
proportion to the amount of protein existent, once a chemiluminescent agent (SuperSignal®) 
was applied. The membrane was viewed under UV light and photographs were taken for 
documantation. 
3.3.3 ELISA  
ELISA (enzyme linked immunosorbent assay) was used on several occasions. For example, 
the binding of antibodies to EGFR coupled beads was controlled by classical sandwich-ELISA. 
8-well strips (Nunc Immunosorp) were incubated with an anti-EGFR capture-antibody (100 µl 
cetuximab, 5µg/ml) at 4°C overnight, chemically binding the capture antibody to the bottom 
of the wells. All following steps were performed at room temperature. The wells were 
washed three times by 200µl ELISA-washing-Buffer each and then incubated for 1h with 
Facs-Buffer. Since Facs-Buffer contains BSA, this step served to block the remaining protein 
binding sites on the wells’ bottom with unspecific protein. 
Now the samples (EGFR coupled beads) were applied together with several standards 
(proteins with known weight) in 7 decreasing concentration steps (dilution 1:2). These 
samples/standards were bound by the capture antibody. After incubation for 1.5h, the strips 
were washed three times again with 200µl ELISA-washing-Buffer each, then incubated for 
1.5h with a murine detection-antibody (m425), which also recognized EGFR. Subsequently, 
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the strips were once more washed three times by 200µl ELISA-washing-Buffer each, then 
incubated for 0.5h by a goat anti-mouse antibody coupled with HRP (horseraddish 
peroxidase), allowing this antibody (gαm-IgG-HRP) to bind to the secondary antibody's Fc 
part. 50µl of o-Phenylenediamine dihydrochloride, a substrate of the HRP, was applied, 
triggering a visible reaction in which the HRP transposed its substrate within a few seconds. 
After 20sec, the reaction was stopped by 3M HCl and the Adsorption of the samples was 
measured in an absorption-reader (Tecan Sunrise) at 492nm wavelength. Since the 
concentration of the proteins working as standards was known, we could derive a calibration 
curve, allowing us to calculate the approximate concentration of EGFR bound to the beads’ 
surface. 
 
 
 
 
 
 
A capture antibody is bound to an 
immunosorbent strip by its Fc part, 
allowing it to bind a antigen on the 
surface of a particle with its Fab 
part. The antigen is then bound by a 
primary antibody, which in turn is 
bound at its Fc part by a secondary 
antibody. Coupled to the Fc part of 
the secondary antibody is an 
enzyme (here HRP= horseraddish 
peroxidase), which can converse an 
uncolored substrate to a visible 
reaction product 
 
 
 
 
Figure 9: Principle of ELISA 
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3.4 Phagocytosis-assay 
We wanted to establish a model for the phagocytosis of tumor cells or parts of tumor cells 
expressing EGFR by granulocytes (PMN) in order to test whether dialysis patients’ ability to 
phagocyte EGFR-coated particles would differ from healthy donors. We chose fluorescent 
polysterene microspheres for this ("beads": Fluoresbrite Carboxylate YG 1.0 Micron 
Microspheres Cat#15702), as they are easy to handle and detect and were available in the 
desired size of 1µm, so the granulocytes could ingest several beads at once. Since we would 
couple EGFR on the surface of the beads, our hypothesis was that the degree of 
phagocytosis observed (number of beads ingested) would depend on the amount of anti-
EGFR antibody applied in the experiment. The antibody would bind the EGFR on the beads 
surface with their Fab part, leaving the Fc part to be detected and consequently bound by 
the FcγR of the granulocytes, thus inducing phagocytosis of the beads. 
Firstly, we tried the coupling of proteins to the surface of microspheres by cheap, easily 
available protein. Polyglobin (Intratect, Biotest Pharma GmbH), i.e. unspecific polyclonal 
human IgGs, was used as a positive control, since the coupling would leave some of the 
antibodies facing outward with their Fc parts, thus encouraging phagocytosis. Albumin (BSA= 
Albumin FraktionV, Carl Roth GmbH) served as a negative control, since it bears no 
resemblance to antibody structure. Later, we coupled EGFR (Genmab, Utrecht). 
Protein was coupled to the beads surface according to the "Carbodiimid-method" of the TDS 
238C from Polysciences Inc.  
0.5ml of Beads-solution (~2.275*1010 Beads, concentration 4.55*107/µl) were washed twice 
with Carbonate-buffer (pH=9.6), then thrice with MES-buffer (pH=6.0). The -COOH groups 
("carboxy goups") on the surface of the beads were then activated by carbodiimid. For this, 
we resuspended the beads in MES-buffer, then added a freshly set up 2% carbodiimid-
solution in a 1:1 dilution and incubated for 3h on a rolling mixer. Since Carbodiimid is known 
to be unstable in hydrous solution and degrade to urea, which in turn denatures protein, the 
Carbodiimid solution had to be freshly set up (younger than 15min) and the beads had to be 
washed twice again with MES-buffer after the incubation. Subsequently, beads were 
resuspended in 0.2M Borate-buffer (pH=8.5). 
Now protein was added. The amount of protein needed to achieve a monolayer of protein 
on the beads surface was calculated according to the manufacturer’s formula: 
S = (6 / ρ * d))*(C) 
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Where S = amount of protein needed for a monolayer 
 ρ = density of microspheres (= 1.05g/cm³) 
 d = diameter of microspheres (= 1µm) 
 C = microsphere capacity for a certain protein (Albumin, MW 65kD → 3mg/m²; IgG, 
MW 150kD → 2.5 mg/m²) 
 
For albumin, we calculated an amount of 18mg albumin / g microspheres. For polyglobin, we 
calculated an amount of 18mg polyglobin / g microspheres. For EGFR, we calculated 21mg / 
g microspheres 
The beads solution purchased by Polysciences Inc consisted of 2.66% beads with a density of 
1.05g/cm³. Thus, there were 1ml*0.0266*1.05 = 0.0273g/ml (= 27.3mg/ml) beads in the 
manufacturers solution. 
The appropriate amount of protein needed was added and incubated on a rolling mixer in 
the dark over night. On the next morning, Ethanolamine was added to saturate -COOH 
groups still unbound by protein. To block unspecific protein binding sites, the beads were 
incubated in Albumin-Solution (10mg BSA in 1ml Borate-buffer) for 30min. 
Lastly, beads were resuspended in 0.5 ml Storage-buffer (0.01M Phosphate-buffer, 1% BSA, 
0.1% Sodium-Acid, 5% Glycerol), delivering a concentration of about 4.55*107 beads/µl. 
To examine the phagocytosis, we incubated 5µl of the beads solution (diluted 1:10, 
~2.275*107 Beads) with 5µl of the antibody (200µg/ml) in a 96 well V-bottom shaped plate 
for 30 min to allow the binding of the antibodies to EGFR. We then set the purified PMN 
obtained from healthy donors to the desired concentration of 107/ml, then added 50µl 
(0.5x106 cells) per well and filled up the wells with medium to 100µl volume. After 
incubation for 120min at 37°C we washed twice with 100µl Facs-buffer and measured the 
cells with flow cytometry. 
When beads coated only with albumin or polyglobin were used, no antibodies were applied, 
only beads and the PMN were incubated for 120min at 37°C. 
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4 Results 
4.1 Comparison of DP and HI ADCC capacity 
We wanted to examine whether differences could be found in the ADCC capacity of ESRD-
patients undergoing regular hemodialysis (DP) from healthy individuals (HI). 
Blood samples were taken from DP before the start of hemodialysis procedure. HI served as 
a control group. 
Since EGFR is expressed on many solid tumors such as colorectal carcinoma or head and 
neck cancer, two FDA-approved antibodies against EGFR which are currently in clinical use 
were used. As an IgG1 antibody, we used cetuximab (marketed by Merck as Erbitux®), a 
chimerical monoclonal antibody approved for the treatment of EGFR positive colorectal 
cancer (about 75% of all colorectal cancer) and head and neck cancer. As an IgG2 antibody, 
we used panitumumab (marketed by Amgen as Vectibix®), a human monoclonal antibody 
approved for the treatment of EGFR positive colorectal cancer. When examining PMN, we 
also used 225 IgA2, since PMN show lower lysis rates with cetuximab than PBMC, but show 
nearly 100% lysis rates with 225 IgA2 when used at saturating concentration. 225 IgA2 was 
therefore used as a positive control for PMN. 
4.1.1 ADCC of neutrophils against A1207 using cetuximab, panitumumab, 225 IgA2 
We firstly examined whether DP would profit from anti-EGFR antibodies to the same extent 
as HI by conducting 51Cr release assays with dilution rows of cetuximab and panitumumab. 
PMN (neutrophils) served as effectors (400,000/well) while A1207 served as targets 
(5000/well) in an E:T-Ratio of 80:1. The specific lysis rate (X-axis) was plotted against the 
antibody concentration (Y-axis). An unspecific antibody was always entrained as a negative 
control. Since 225 IgA2 has been shown to mediate strong ADCC with PMN, 225 IgA2 was 
entrained as a positive control. 
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ADCC by 3 different Abs cetuximab (A), 
panitumumab (B) and 225-IgA2 (C) at increasing 
concentrations was analyzed in 51Cr release assay 
against A1207 cells using PMN obtained from 
blood samples of HI (square, gray line) or DP 
(point, black line). Data presented are means ± 
SEM of 8 (B) or 10 experiments (A, C). 
Significance was accepted when p < 0.05. An 
asterisk (*) indicates significant specific lysis 
compared to control antibody (open circle, light 
gray line). 
While the specific lysis rates of DP with PMN was slightly higher than that of HI and also the 
EC50 was slightly lower for cetuximab, panitumumab and 225 IgA2, the difference was far 
from significant. 
Antibody HI-mean (95%CI) DP-mean (95%CI) 
cetuximab 
 plateau (95%CI) 
 EC50 (95%CI) 
 
29.5 (21.3-37.7) 
0.064 (0.024-0.168) 
 
32.5 (22.8-42.1) 
0.030 (0.008-0.112) 
panitumumab 
 plateau (95%CI) 
 EC50 (95%CI) 
 
58.8 (49.2-68.3) 
0.038 (0.02-0.08) 
 
64.5 (51.7-77.2) 
0.024 (0.010-0.054) 
225 IgA2 
 plateau (95%CI) 
 EC50 (95%CI) 
 
101.8 (95.6-107.9) 
0.029 (0.023-0.038) 
 
102.0 (94.9-109.2) 
0.023 (0.017-0.030) 
Table 5: Corresponding data for figure 10 
Figure 10: Cetuximab (IgG1), panitumumab 
(IgG2), and 225 IgA2 show the same lysis rates 
with PMN drawn from dialysis patients (DP) as 
with PMN drawn from healthy individuals (HI) 
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4.1.2 ADCC of mononuclear cells against A1207 using cetuximab, panitumumab 
The lysis rates of DP with PBMC and cetuximab bore no significant difference, similar to the 
PMN with cetuximab. For panitumumab, however, a significant difference was observed at 
the three highest concentrations (0.08, 0.4 and 2µg/ml). 
The data indicated a normal distribution of the measurements according to D'Agostino & 
Pearson omnibus K2 normality test. Main effect in 2-way-ANOVA: no significance between 
cases: P=0.133, F=2.30; significant difference between healthy/dialysis: P<0.0001, F=24.99. 
Then paired T-Test, two-tailed: P=0.005, 0.005, 0.006 and R²=0.71, 0.70 and 0.68 for 
antibody concentrations of 2µg/ml, 0.4µg/ml and 0.08µg/ml, respectively. 
 
ADCC by 2 different antibodies cetuximab (A) and panitumumab (B) at increasing concentrations 
was analyzed in 51Cr release assay against A1207 cells using PBMC obtained from blood samples of 
HI (square, gray line) or DP (point, black line). Data presented are means ± SEM of 8 (B) or 10 
experiments (A). Significance was accepted when p < 0.05. An asterisk (*) indicates significant 
specific lysis compared to control antibody (open circle, light gray line); pound (#) indicates 
significant difference between HI and DP. 
 
Antibody HI-mean (95%CI) DP-mean (95%CI) 
cetuximab 
 Plateau (95%CI) 
 EC50 (95%CI) 
 
53.5 (48.2-58.9) 
0.005 (0.003-0.008) 
 
59.4 (53.7-65.0) 
0.010 (0.006-0.016) 
panitumumab 
 Plateau (95%CI) 
 EC50 (95%CI) 
 
17.4 (10.8-24.1) 
0.022 (0.004-0.112) 
 
46.5 (38.3-54.7) 
0.023 (0.011-0.047) 
Table 6: Corresponding data for figure 11 
Figure 11: Cetuximab shows the same lysis rate with PBMC drawn from DP as with PBMC drawn 
from HI. Panitumumab shows significantly higher lysis rates with PBMC from DP than from HI 
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4.1.3 ADCC of mononuclear cells against A431 using cetuximab, panitumumab 
Similar experiments were now performed on another target cell line expressing EGFR, A431. 
PBMC of HI and DP were compared by 51Cr release assays with a single antibody 
concentration of cetuximab and panitumumab, reliably in the saturating region (2µg/ml). 
Once again, we found slightly elevated rates of specific lysis for DP, but the differences were 
not significant (n=8, HI-mean=34.7, 95%CI 17.7-51.6. DP-mean=48.5, 95%CI 33.0-64.0; 
R²=0.278; P=0.145). For panitumumab, we once again observed significantly elevated rate of 
specific lysis of DP over HI (n=8, HI-mean=9.0, 95%CI 1.7-16.4; DP-mean=15.7, 95%CI 7.0-
24.4; P=0.040; R²=0.474. paired T-Test, two-tailed).  
 
ADCC by 2 different antibodies cetuximab (A) and panitumumab (B) at 2µg/ml concentration was 
analyzed in 51Cr release assay against A431 cells using PBMC obtained from blood samples of HI 
(light gray bar) or DP  (dark gray bar). White bars indicate background lysis by respective effectors 
via control Ab. Data presented are means ± SEM of 8 experiments. Significance was accepted when 
p < 0.05. An asterisk (*) indicates significant specific lysis compared to control antibody; pound (#) 
indicates significant difference between HI and DP. 
 
 
 
 
 
Figure 12: Cetuximab shows slightly higher lysis rates on PBMC drawn from DP as on PBMC drawn 
from HI. Panitumumab shows significantly higher lysis rates with PBMC from DP than from HI 
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4.2 Phagocytosis assay 
We had observed an effect of DP's PBMC showing an increased capacity in IgG2-mediated 
ADCC. We now wanted to see whether this meant that other antibody-dependent methods 
of defense against tumor cells expressing EGFR like phagocytosis were altered in DP as well. 
Therefore, we had to establish an assay for antibody-dependent phagocytosis. As a model, 
we chose EGFR-coated microbeads (=polysterene microspheres), which can easily be 
detected by flow cytometry. 
4.2.1 General practicability, setup of the assay 
We first had to successfully couple protein to the bead's surface, then in a next step set out 
to examine which parameters influenced the phagocytosis of the beads by neutrophils 
(PMN). In order to show general practicability of the assay, we first coupled the readily 
available polyglobin (unspecific polyclonal human IgGs, used as a positive control), and 
albumin (BSA, Albumin FraktionV, used as a negative control). We wanted to determine 
optimal experimental conditions and find out factors the phagocytosis depended on so that 
we could improve the assay. 
For the phagocytosis assay, we incubated granulocytes obtained from HI with beads, washed 
twice with Facs-buffer, then measured the cells using flow cytometry (data shown here was 
measured in Epics XL-MCL, Beckman Coulter). Since the beads are fluorescent at 520nm 
wavelength (channel F1 in Epics XL-MCL), we could identify the cells that had absorbed 
fluorescent beads. 
We could show that phagocytosis was influenced by the following parameters: 
 Amount of protein coupled to the beads surface: more protein meant higher rate of 
phagocytosis (see figure 14) 
 Incubation time: longer incubation time meant higher rate of phagocytosis (30, 75, 
120, 240min.) (see figure 15) 
 Stimulation of PMN: adding GM-CSF unspecifically activated the granulocytes to a 
higher rate of phagocytosis for albumin as well as polyglobin (see figure 16) 
 Temperature during incubation: while phagocytosis was observed when incubating at 
37°C, practically no phagocytosis occurred when incubating at 0°C, even if GM-CSF 
was added (see figure 17) 
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The following pictures show 3 graphs per measured sample: FSClin/SSClin on the left, 
F1LOG/SSClin in the middle and F1LOG on the right. The gate "PMN" in FSClin/SSClin is located to 
fit the solitary PMN and the PMN that have ingested beads, and exclude the solitary beads. 
The next window, F1LOG/SSClin , only shows events from "PMN", and F1 (X-axis) is plotted 
against SSC (Y-axis). As PMN ingest more beads, they become more granular, thus receiving 
higher measurement in SSC, and the beads within the PMN make the cell more fluorescent, 
thus measuring peaks in the F1 channel. The last window, F1LOG , shows only the F1 channel 
of the "PMN" gate. As more beads get ingested by PMN, peaks appear on the right side of 
the window, indicating fluorescent cells. Besides the first big peak (only PMN), the first 
couple of peaks can be identified, interpreted as PMN having ingested one, two and more 
beads.  
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Figure 13: Typical flow cytometry data from phagocytosis assay 
PMN alone (A), beads alone (B), PMN + beads coupled with albumin (C),  PMN + beads coupled with 
polyglobin (D), all after incubation at 37°C for 120min. Pictures show 3 graphs per measured sample: 
FSClin/SSClin, (left) F1LOG/SSClin (middle) and F1LOG  (right). The gate seen on the right in the F1LOG  
window contains the PMN that ingested fluorescent beads. 
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A: small amount of protein 
B: large amount of protein 
Figure 14: Rate of phagocytosis is influenced by the amount of protein coupled to the beads 
surface 
Incubation of PMN and beads coated with small (A) or large (B) amounts of polyglobin for 120min at 
37°C. 
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A: 30min 
B: 75min. 
C: 120min. 
Figure 15: Rate of phagocytosis is influenced by the incubation time 
Incubation of PMN with beads coated with polyglobin for 30 (A), 75 (B) and 120min (C) at 37°C. 
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A: Albumin beads 
B: Albumin beads with GM-CSF 
C: Polyglobin beads  
D: Polyglobin beads with GM-CSF  
Figure 16: Stimulation of PMN by adding GM-CSF unspecifically activates the granulocytes 
A higher rate of phagocytosis can be observed when incubating PMN with GM-CSF (B and D) and 
beads coupled with albumin (A and B) as well as polyglobin (C and D), although the effect is 
remarkably higher on polyglobin-coupled beads. All incubated at 37°C for 120min. 
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A: incubated at 0°C  
B: incubated at 0°C with GM-CSF  
C: incubated at 37°C  
D: incubated at 37°C with GM-CSF  
Figure 17: Rate of phagocytosis is influenced by the temperature during incubation 
PMN are incubated with beads coupled with polyglobin for 120min at 0°C (A and B) and at 37°C (C 
and D) without (A and C) and with GM-CSF (B and D). 
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We also experimented with the shape of wells in the 96 well plates used (V-bottom vs. Flat 
bottom, no difference observed, no pictures shown) and the total volume in which to 
incubate the PMN and the beads for the given time (100, 150, 200µl; no significant 
difference observed but defined 100µl as standard procedure for easier handling, no 
pictures shown). We then determined it was best to incubate the beads and the Abs without 
the PMN first for 30min (allowing the Abs to bind to the EGFR on the beads surface), then 
adding the PMN and incubating for 120min. 
As the optimum of experimental conditions, we identified: 
1. Coupling an amount of protein to the beads surface to suffice for at least one 
monolayer 
2. First add the beads and antibodies, incubate for 30min, then add PMN, fill to 
100µl/well, then incubate. 
3. 120min of incubation time at 37°C 
4. No GM-CSF added, as this activated the granulocytes unspecifically, inducing 
phagocytosis of practically everything (even uncoated or albumin-coated beads) 
5. Incubation in a V-bottom shaped 96 well plate (easier handling than flat bottom) 
6. 100µl of incubation volume (easier handling than higher volumes) 
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4.2.2 Coupling of EGFR to microspheres 
In a next step, we coupled EGFR on the beads' surface. Since only a few mg of this rather 
expensive protein were available, we down-scaled the coupling assay by 1/10th, starting with 
50µl of beads-solution instead of 0.5ml. The calculated amount of EGFR for one monolayer 
when starting with 50µl of beads-solution was about 22µg. 
Since the process of coupling protein to the beads surface involved chemicals with 
potentially denaturing effect (most notably ethanolamine and carbodiimid), we tried three 
different coupling procedures. 
1. Covalent coupling according to the manufacturer’s instructions ("carbodiimid-
method", see methods, from Polyscience TDS 238C). Included ethanolamine and 
carbodiimid. 
2. Covalent coupling ("carbodiimid-method"). Without ethanolamine. 
3. Coupling by adsorption to non-carboxylated beads (Fluoresbrite Plain YG 1.0 Micron 
Microspheres Cat#17154) according to manufacturer’s instructions (Polyscience TDS 
238E). Without ethanolamine or carbodiimid. 
For the phagocytosis assays of the EGFR coated beads, we incubated PMN with different 
Abs: Cetuximab (IgG1) and panitumumab (IgG2) as anti-EGFR antibodies, unspecific IgG1 or 
IgG2, or antibodies directed against other antigens such as rituximab (CD20) or trastuzumab 
(HER2/neu, both IgG1) as control antibodies. 
No difference was observed between 1. and 2. The method of coupling protein to the 
surface of beads by adsorption (3.) was abandoned, since differences between albumin-
coated and EGFR-coated beads were smaller than with the covalently coupled proteins (no 
pictures shown). 
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4.2.3 Assay for IgG antibodies 
In our first ADCC experiments, we had observed a heightened ADCC capacity of DP's PBMC 
with IgG2. We wanted to examine whether this effect indicated a higher rate of IgG2 
mediated phagocytosis of EGFR-coated beads, as well. We observed a higher rate of EGFR-
coated beads ingested by PMN when they were incubated with panitumumab (37%) than 
without antibodies (3%), or with unspecific IgG2 (17%).  
 
 
 
 
Figure 18: Phagocytosis of EGFR-coated polysterene microspheres (beads) influenced by 
specificity of IgG2 antibody 
Of PMN incubated with EGFR-coated beads and no antibody (A), about 3% ingest beads. Of PMN 
incubated with EGFR-coated beads and unspecific IgG2 (B), about 17% ingest beads. Of PMN 
incubated with EGFR-coated beads and panitumumab (C), about 37% ingest beads. 
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In an immunofluorescence flow cytometry testing, we examined whether or not 
panitumumab bound to the EGFR-coated beads by first incubating beads and panitumumab, 
then adding a secondary antibody against human IgG, marked by another fluorophore (gαh 
PerCP anti-human IgG, diluted 1:20). 47% of the beads were bound by panitumumab, while 
only 1% of the beads were bound by the corresponding control antibody.  
 
 
 
Figure 19: IgG2 antibody panitumumab binds EGFR coupled to the surface of polysterene 
microspheres (beads), its control antibody (unspecific IgG2) does not 
Beads coupled with EGFR were incubated for 30min at 37°C with  unspecific IgG2 (A) or 
panitumumab (B), then subsequently incubated with a secondary antibody (gαh PerCP anti-human 
IgG) for another 30min at 37°C, then measured using flow cytometry. Beads fluoresced in F1, while 
the fluorophore of the secondary antibody fluoresced in channel F4. Pictures show 3 graphs per 
measured sample: FSClin/SSClin, (left) F1LOG (middle) and F1LOG /F4LOG (right). The upper right gate in 
F1LOG /F4LOG shows the beads bound by the IgG2 Ab. About 1.4% of the EGFR-coated beads were 
bound by unspecific IgG2 (A), while about 46.7% of the EGFR-coated beads were bound by 
panitumumab (B, lower right).  
 
However, we were unable to reproduce this effect for the IgG1 antibodies and when we 
examined the circumstances more closely, problems started to occur. At first we tested 
cetuximab and its control antibody, unspecific human IgG1 in the phagocytosis assay, finding 
an even higher phagocytosis rate in unspecific IgG1 than in cetuximab.  
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When we tested the binding ability of cetuximab to the EGFR-coated beads in an 
immunofluorescence flow cytometry experiment, we found that both cetuximab and its 
control antibody did not bind to the EGFR-coated beads.  
We then tested several other IgG1 antibodies, including 003, 005, 018, 2F8T, hR3 and h425 
directed against EGFR, as well as unspecific IgG1, IgG2 and Herceptin (also IgG1) directed 
against antigens other than EGFR. We tested both for induction of phagocytosis and for the 
antibodies’ binding capacity of the EGFR-coated beads via immunofluorescence and flow 
cytometry. The antibodies showed a big diversity in the phagocytosis rates they induced. 
Consistent rates of phagocytosis were found for each antibody in repeated measurements.  
Confusingly, the phagocytosis rates did not correspond with the binding capacity to the bead 
of that particular antibody. The following table gives an overview of phagocytosis / binding 
capacity interactions. 
 
Antibody Phagocytosis [%] binding capacity of beads [%] 
anti-EGFR Abs 
cetuximab 25.0 4.4 
panitumumab 29.1 46.7 
OO3 45.2 7.1 
OO5 37.3 70.9 
O18 24.8 57.0 
2F8T 33 28.1 
hR3 37.2 4.0 
h425 23.3 49.5 
unspecific Abs 
IgG1 41.6 1.4 
IgG2 12.1 1.4 
Herceptin 17.5 2.5 
Table 7: Phagocytosis and bead-binding capacity of several antibodies 
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We found Panitumumab, 005, 018 and h425 binding well to the EGFR-coated beads, while 
cetuximab, 003 and hR3 did not bind at all. 
Some of the Abs which did not bind to the beads induced phagocytosis by neutrophils (e.g. 
003: 45% phagocytosis, 7.1% binding) and several of the Abs that did bind the beads induced 
less phagocytosis (e.g. 005: 37% phagocytosis, 70.1% binding). 
With a large number of tested Abs and the inconsistency in phagocytosis-binding capacity, 
the data indicated that the antibody-dependent phagocytosis of EGFR coated beads did not 
work with the construct of EGFR used here. This may be caused by an alteration of the EGFR 
protein during the coupling process, resulting in a loss of recognition by the Abs for its 
specific EGFR epitope. More experiments have to be conducted in order to solve these 
issues, a task that was beyond the scope of this doctoral thesis. 
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4.3 Differences in mononuclear cells' ADCC capacity further examined 
4.3.1 ADCC of monocytes against A431 using cetuximab, panitumumab 
We wanted to examine the effect of PBMC's increased ADCC capacity in DP further. Within 
the heterogeneous population of PBMC, several subpopulations came to mind which could 
have been responsible for the observed effect, foremost monocytes and NK-cells, as both 
have been shown to mediate ADCC.  
We first conducted a series of experiments of 51Cr release assays with purified monocytes 
("untouched") against A431 at a single antibody concentration of cetuximab and 
panitumumab, reliably in the saturating region (2µg/ml). Monocytes of DP showed a higher 
rate of specific lysis with cetuximab over monocytes of HI, but not significantly elevated 
(n=5, HI-mean=11.9, 95%CI 3.00-20.81. DP-mean=20.74, 95%CI 6.19-35.29; R²=0.4510; 
P=0.1441 Paired T-Test, two-tailed). With panitumumab, we found a significantly higher 
specific lysis rate of DP's monocytes over HI's monocytes (n=5, HI-mean=8.90, 95%CI 0.35-
17.45; DP-mean=20.48, 95%CI 6.52-34.44; R²=0.7641 P=0.0228. Paired T-Test, two-tailed). 
 
Figure 20: Cetuximab shows slightly higher lysis rates with monocytes drawn from DP than with 
monocytes drawn from HI. Panitumumab shows significantly higher lysis rates with DP's 
monocytes than HI's monocytes 
ADCC by 2 different antibody cetuximab (A) and panitumumab (B) at 2µg/ml concentration was 
analyzed in 51Cr release assay against A431 cells using monocytes obtained from blood samples of 
HI (light gray bar) or DP (dark gray bar). White bars indicate background lysis by respective effectors 
via control Ab. Data presented are means ± SEM of 8 experiments. Significance was accepted when 
p < 0.05. An asterisk (*) indicates significant specific lysis compared to control antibody; pound (#) 
indicates significant difference between HI and DP. 
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Since these experiments were performed at the same E:T ratio for HI and DP, the data 
indicates an enhanced ADCC capacity of DP's monocytes. 
4.3.2 FcR quantification on monocytes and neutrophils 
One hypothesis for the explanation of the heightened state of activation of DP monocytes 
over HI monocytes was the different expression of FcR, most notably CD32 (FcγRII). 
It has been shown that the IgG2-antibody panitumumab, for which a significant difference 
was observed in ADCC lysis rate of the PBMC and monocytes between HI and DP, is most 
strongly bound with its Fc part by CD3259. The expression of CD32 was therefore especially 
interesting. 
In order to quantify the FcR, we used the Qifikit (Dako) on purified monocytes (“untouched”) 
and PMN. However, monocytes as well as PMN showed no significant difference in the 
expression of FcR.  
 
Figure 21: Quantification of Fc-receptors on monocytes and PMN from both HI and DP reveals 
roughly the same levels 
Monocytes (purified "untouched") and PMN were obtained from blood samples of HI (light gray 
bars) or DP (dark gray bars). Data presented are means ± SEM of 6 to 19 experiments.  
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4.3.3 NK-cells examined for CD32 expression 
Having found no difference in FcR expression of DP's monocytes, we wanted to examine 
whether or not NK-cells of DP expressed CD32 on their surface. In HI, there is no expression 
of CD32 on NK-cells.  
For this, we purified NK-cells from pairs of HI and DP and examined them by direct 
immunofluorescence (CD45-FITC, 7AAD-PC-5, IgG-PE or CD32-PE, CD56-PC-7) and flow 
cytometry. NK-cells were defined as lying in the lymphocytes gate in FSC/SSC, CD45+, 7AAD-
neg. (=vital), CD56+.  
At n=4 pairs of HI/DP, we found no CD32 on NK-cell surface. 
 
Figure 22: NK-cells of DP do not express CD32 
Flow cytometry analysis of   direct immunofluorescence. Cells were dyed with CD45-FITC, 7AAD-PC-
5, IgG-PE or CD32-PE, CD56-PC-7. Successively, we gated on CD45+ cells (A) and 7AAD-negative 
=vital cells (B). FSC/SSC (C) was used to gate on lymphocytes (D, blue) according to size (FSC) and 
granularity (SSC). NK-cells were then defined as lying in the lymphocytes gate, CD56+. Of these, 
close to 0% showed to be CD32+ when compared to the negative control (unspecific IgG-PE, not 
shown). Red=monocyte gate. The shown pictures are representative for n=4 pairs of HI/DP. 
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4.3.4 Quantification of PBMC-subpopulations 
Another explanation of the observed effect of DP's PBMC showing increased ADCC activity 
with panitumumab was found when analyzing the composition of the heterogeneous PBMC 
population. For n=4 pairs of HI/DP, PBMC were purified and dyed with several Antibodies, 
allowing us to quantify the individual subpopulations that make up the PBMC population. 
The following table shows the antibodies used: 
Tube Nr. HI or DP FITC PE ECD PC-5 PC-7 
1 HI CD45 IgG IgG 7AAD IgG 
2 HI CD45 CD32 CD16 7AAD CD56 
3 HI CD45 CD32 CD14 7AAD CD56 
4 HI CD45 CD19 CD3 7AAD CD56 
5 DP CD45 IgG IgG 7AAD IgG 
6 DP CD45 CD32 CD16 7AAD CD56 
7 DP CD45 CD32 CD14 7AAD CD56 
8 DP CD45 CD19 CD3 7AAD CD56 
Table 8: antibodies used for quantification of PBMC subpopulations 
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Figure 23: Typical Flow cytometry data from quantification of the PBMCs subpopulations 
Flow cytometry analysis of direct immunofluorescence of several samples from one dialysis patient. 
Cells were dyed with CD45-FITC, 7AAD-PC-5, IgG-PE or CD32-PE or CD19-PE, IgG-ECD or CD16-ECD 
or CD3-ECD, IgG-PC-7 or CD56-PC-7. Successively, we gated on CD45+ cells (A) and 7AAD-negative 
=vital cells (B). FSC/SSC (C) was used to gate on monocytes (D, red) or lymphocytes (E-I, blue) 
according to size (FSC) and granularity (SSC). The shown pictures are representative for n=4 pairs of 
H/D. 
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The following table shows the definition of the PBMC subpopulations used for the 
quantification: 
 
PBMC-Subpopulations gate 
Monocytes CD14+ in monocyte gate in FSC/SSC of CD45+, vital cells 
Lymphocytes Lymphocyte gate in FSC/SSC of CD45+, vital cells 
T-cells CD3+ in lymphocyte gate in FSC/SSC of CD45+, vital cells 
B-cells CD19+ in lymphocyte gate in FSC/SSC of CD45+, vital cells 
NK-cells("NK") CD56+ in lymphocyte gate in FSC/SSC of CD45+, vital cells 
CTNK-cells ("CTNK") CD16+ and CD56+ in lymphocyte gate in FSC/SSC of CD45+, vital cells 
Table 9: Gates used for quantification of PBMC subpopulations 
 
 
Significantly elevated levels of monocytes in DP were observed compared to HI. In 
lymphocytes, DP showed significantly lower percentages than HI, while the decrease in 
lymphocytes was mostly due to the reduction of T-cells in DP over HI. The other populations 
analyzed, namely B-cells, NK-cells and CTNK-cells (= cytotoxic NK-cells) showed no significant 
difference between HI and DP. (n=4. Mean of HI's monocytes=11.4, 95%CI 3.2-19.5; mean of 
DP's monocytes=30.5, 95%CI 17.4-43.5; P=0.037; R²=0.81.  
Mean of HI's lymphocytes=80.7, 95%CI 69.4-91.9; mean of DP's lymphocytes=53.1, 95%CI 
32.2-74.1; P=0.045; R²=0.79.  
Mean of HI's NK=15.0, 95%CI 5.2-24.8; mean of DP's NK=16.3, 95%CI 2.6-30.2.  
Mean of HI's CTNK=10.3, 95%CI 0.4-30.2; mean of DP's CTNK=10.5, 95%CI 3.6-17.5. Mean of 
HI's T-cells=56.3, 95%CI 41.3-71.4; mean of DP's T-cells=32.7, 95%CI 0.0-67.5; P=0.114; 
R²=0.79. 
Mean of HI's B-cell=5.1, 95%CI 0.0-12.7; mean of DP's B-cell=4.4, 95%CI 0.0-12.5. Paired T-
test, two-tailed. ) 
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Figure 24: Differences in PBMC composition in HI and DP 
PBMC from both groups (HI, gray bars; DP, black bars) were obtained from blood samples, then 
subsequently analyzed using direct immunofluorescence and flow cytometry. Monocytes were 
defined as CD14+ in FSC/SSC monocyte-gate of CD45+, vital cells. Lymphocytes were defined as 
FS/SS-lymphocyte-gate in CD45+, vital cells. Natural killer cells („NK“) were defined as CD56+ in 
FS/SS-lymphocyte-gate of CD45+, vital cells. Cytotoxic natural killer cells („CTNK“) were defined as 
both CD16+ and CD56+ in FS/SS-lymphocyte-gate of CD45+, vital cells. T-cells were defined as CD3+ 
in FS/SS-lymphocyte-gate of CD45+, vital cells. B-cells were defined as CD19+ in FS/SS-lymphocyte-
gate of CD45+, vital cells. Data presented are means ± SEM of 4 experiments. Significance was 
accepted when p < 0.05. Pound (#) indicates significantly different percentages between HI and DP. 
 
 
This data indicates that the increased ability of the PMBC in DP to mediate ADCC with IgG2 
Abs can be attributed to two different causes. The first is the heightened state of monocyte 
activation in DP, while the second is the heightened proportion of monocytes among the 
subpopulations of the PBMC in DP. 
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5 Discussion 
The concept of personalized tumor therapy aims to select the right drug for the right patient, 
among others by determination of a variety of biomarkers60. As examples for specific tumor 
characteristics, EGFR kinase mutations were positively correlated with response to EGFR 
tyrosine kinase inhibitors erlotinib and gefitinib in lung cancer, whereas the presence of 
KRAS mutations was highly predictive of resistance to EGFR-antibodies cetuximab and 
panitumumab in colorectal cancer. As example for predictive patient characteristics, FcγR 
polymorphisms were demonstrated to influence the outcome of treatment with cetuximab 
in colorectal cancer61. 
In this context, the aim of this study was to compare leukocytes of patients with ESRD 
undergoing regular hemodialysis (DP) to those of healthy individuals (HI) in their capacity to 
kill tumor cells with the mediation of antibodies. To our knowledge, only three studies are 
published addressing ADCC in DP at all. These studies are rather incomplete and results 
remain unclear. In one study, isolated PBMC of DP were tested in ADCC against chicken red 
blood cells (CRBC). Results were heterogeneous: PBMC from some patients performed 
better, some identical and some worse than PBMC from HI54. The other two studies can 
hardly be interpreted as they only used phagocyte depleted lymphocytes as effectors55, 62. 
We used the EGFR as target antigen, as it is overexpressed on many solid tumors and has 
been shown to play an important role in development and growth of tumors. To date, two 
EGFR-specific antibodies are FDA approved: cetuximab, which is of human IgG1 isotype, and 
panitumumab, which is of human IgG2 isotype. Comparison of both antibodies seemed 
especially interesting since due to their divergent isotypes both differ in their binding 
characteristics to FcR and thus in their recruitment of effector cell populations. 
We planned to examine the two main indirect effector mechanisms, ADCC and phagocytosis. 
The classical 51Cr release assay has already been established in the lab group as an in vitro 
model for ADCC, whereas a method to test antibody-mediated phagocytosis had to be 
established.  
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5.1 ADCC of PMN and PBMC 
With isolated neutrophils (PMN) as effector cells, both EGFR-antibodies significantly 
triggered ADCC against EGFR-expressing A1207 tumor cell line, and the human IgG2 antibody 
panitumumab proved to be significantly more effective than the IgG1 antibody cetuximab, 
as described before59. However, we did not observe any difference between PMN isolated 
from DP and HI. 
We then tested PBMC effector cells consisting mainly of lymphocytes, NK-cells and 
monocytes. With these effectors, ADCC levels were generally higher when mediated by 
antibodies of the IgG1 isotype than IgG2, an effect also described before59. With IgG1 
antibody cetuximab, PBMC-ADCC was similar between DP and HI.  
Interestingly, however, we observed a strong and significant difference in IgG2-mediated 
ADCC comparing DP and HI: PBMC from DP proved to be significantly more cytotoxic than 
those from HI. To exclude a cell line specific effect, we performed corresponding ADCC 
experiments with a second EGFR-positive tumor cell line, A431, confirming these results. 
5.2 Antibody-dependent phagocytosis  
Next, we aimed to investigate if this effect was restricted to ADCC or if it occurred in 
phagocytosis as well. Therefore, we had to establish an assay for antibody-dependent 
phagocytosis. As a model, we chose EGFR-coated microbeads, which can easily be detected 
by flow cytometry. 
Using polyglobin- and albumin-coated beads as positive or negative control, we determined 
optimal experimental conditions to maximize the observed phagocytosis effect. 
Phagocytosis rate proved to depend on a number of conditions such as incubation time, 
temperature, amount of protein coated on the beads surface and activation status of the 
effector cells. Importantly, principal conductibility and practicability of the chosen method 
could be demonstrated. 
To test for antigen specific phagocytosis and influence of the antibodies isotype on the 
phagocytosis process, we coupled recombinantly produced EGFR to the beads surface. 
However, during the coupling process antigen characteristics of EGFR were obviously 
altered, resulting in EGFR-antibodies being unable to specifically bind to the beads. Most 
likely, the tertiary structure of EGFR was changed by the coupling conditions. We tried 
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various coupling conditions and beads, but failed to set up a stable and reliable test. Further 
experiments need to be conducted to optimize the assay, thus allowing investigation of 
antigen specific antibody-dependent phagocytosis. Amongst others, additional beads and 
coupling procedures have to be tried, as well as different recombinantly produced EGFR 
constructs. This task, however, was beyond the scope of this doctoral thesis. 
 
5.3 Mechanisms of increased IgG2-mediated ADCC in DP further 
examined  
Next, we searched for the underlying mechanism of the observed improved IgG2-mediated 
ADCC capacity of PBMC from DP. Basically, three mechanisms were to be considered:  
Firstly, cytotoxic cells of DP could be preactivated. 
Secondly, certain cytotoxic cell subpopulations may be altered in DP, e.g. in terms of 
different expression patterns of FcγR.  
Thirdly, DP may have more cytotoxic cells susceptible to triggering ADCC by IgG2 antibodies.  
5.3.1 Increased activation of DP's monocytes 
Human IgG2 antibodies have been demonstrated not to bind to FcγRI (CD64) and to bind to 
FcγRIII (CD16) only at concentrations high above the physiological level. However, human 
IgG2 antibodies have been shown to bind strongly to FcγRII (CD32), in particular to the 
activatory FcγRIIa59. Within PBMC, the only cytotoxic cells naturally expressing FcγRIIa on 
their surface are monocytes. Therefore, we conducted a series of experiments examining 
ADCC capacity of monocytes of DP and HI, respectively. With isolated monocytes as 
effectors, we observed the same effects as with the unseparated PBMC: ADCC levels with 
effectors from DP were higher compared to HI with both the IgG1 and the IgG2 antibody, but 
the difference in IgG2-mediated ADCC was stronger and statistically significant. As we 
employed the monocytes at a fixed effector-to-target-ratio, this result indicated an activated 
state of monocytes in DP.  
We also observed an increased ratio of CD14+ CD16+ monocytes in DP, an effect described 
before63. 
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5.3.2 Differences in FcR expression of monocytes and PMN 
As differences in FcR expression, in particular FcγRIIa, could explain the improved ADCC 
capacity of monocytes in DP, we measured expression levels of cytotoxic trigger molecules 
FcγRI, FcγRII, FcγRIII and FcαR on monocytes and on PMN. However, we could not observe 
any significant difference between DP and HI. Thus, the different state of activation 
observed in DP monocytes is likely to be due to a mechanism downstream the signaling 
cascade of FcR, allowing a stronger response to FcR-binding while maintaining the same level 
of FcR surface expression.  
In our flow cytometry assays, we formally did not distinguish between the activatory FcγRIIa 
and the inhibitory FcγRIIb isoform. But as normal monocytes hardly express relevant 
numbers of FcγRIIb on their surface64, an altered ratio of FcγRIIa to FcγRIIb (referred to as 
activating-to-inhibitiory or A/I-ratio) in DP could only result in weaker triggering of 
monocytes by binding of IgG2 in DP. One would thus expect lower lysis rates in DP and not 
higher ones as observed. Lastly, there are no recombinant murine antibodies available that 
exclusively target FcγRIIa or FcγRIIb, respectively and thus would allow one to determine the 
expression of FcγRII-subtypes. 
5.3.3 FcRII expression on NK-cells 
In order to confirm that monocytes are the major subgroup of PBMC to generate the 
increased IgG2-mediated ADCC capacity in DP, we examined the role of additional PBMC-
subpopulations, and whether they expressed FcγRII on their surface. NK cells are the main 
cytotoxic cells for IgG1-mediated ADCC and subsets of NK cells have been demonstrated to 
express FcγRII to some extent on their surface65. However, we could not detect FcγRII 
expression on the surface of NK cells either in DP or HI. 
5.3.4 Biocompatibility and activation of leukocytes 
A possible reason for the activated state of DP's leukocytes could be the blood's continuous 
contact with foreign surfaces while passing through the dialysis machine. Biocompatibility 
has been markedly improved in recent years by the production of more advanced 
membranes, but the foreign surfaces still lead to strong effects in the blood. Different types 
of dialysis membranes have been demonstrated to affect aggregation and activation of 
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leukocytes to a varying degree66. The hydroxyl groups of plastic seem to play an important 
role in the activation of blood components, as indicated by studies demonstrating 
membranes with less hydroxyl groups to reduce the relative risk of mortality in DP67. Certain 
Synthetic membranes lead to different expression patterns of genes contributing to cell 
adhesion68. 
The complement system (C3a, C5a) has also been proven to become activated by contact to 
hydroxyl groups69,70. Activated complement can induce chemotaxis and increased adherence 
of leukocytes to the endothelium71. Additionally, it has been demonstrated that gene 
expression patterns in PBMC vary according to the employed membrane. Mitochondrial 
dysfunction and apoptosis in PBMC was observed during hemodialysis sessions72. 
In summary, this data suggests an increased activation status of leukocytes in DP, consistent 
with the results of our study. However, further studies are required to explore why this 
difference seemed to be restricted to monocytes, and could not be observed in PMN in our 
study. Furthermore, it is unclear why monocyte activation results in significantly increased 
ADCC via the IgG2 but not via the IgG1 antibody. 
5.3.5 Differences in PBMC composition 
Next, we were interested if FcγRII-expressing cytotoxic cells were numerically expanded in 
DP. Therefore, we measured composition of PBMC subpopulations in DP and HI by 5-color 
flow cytometry, sorting cells according to size, granularity, vitality and expression of typical 
antigens. T-lymphocyte numbers were found to be decreased in DP. Since T-cells play an 
integral role in the defense against tumor cells, decreased cell count might contribute to the 
observed higher tumor incidence in DP27. Interestingly, monocyte numbers were significantly 
increased in DP compared to HI. This increased absolute number of monocytes combined 
with the activated status of monocytes could explain the observed superior IgG2-mediated 
ADCC capacity of DP’s PBMC. An increased monocytic cell number in DP has been described 
before73, 74. The mechanisms that lead to increased monocyte counts in DP are still unclear, 
but systemic microinflammation and an altered cytokine environment, e.g. elevated 
macrophage colony-stimulating factor (M-CSF)73, 75 are likely to be responsible.  
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5.4 Conclusion 
In summary, our experiments demonstrate that cytotoxic effector cells (both PMN and 
PBMC) of patients with end-stage renal disease undergoing dialysis are fully capable of 
antibody mediated tumor cell killing. We did not find any evidence that DP’s ability to 
perform ADCC is diminished compared to HI. Thus, we do not see any rational reason to 
withhold antibody-mediated tumor therapies from DP. Furthermore, our studies indicate 
that dialysis patients might profit particularly from certain therapeutic approaches which 
recruit monocytes as effector cells, such as IgG2 antibodies. 
5.5 Publication 
Parts of this thesis were published in the American Journal of Nephrology. The contribution 
entitled “Antibody dependent cellular cytotoxicity in patients on chronic hemodialysis” by 
Koch et al76 appeared in October 2013. PMID: 24157422  
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6 Summary 
Patients suffering from chronic kidney failure undergoing regular hemodialysis (DP) have 
been shown to suffer from increased incidence of solid tumors (e.g. colorectal carcinoma), 
which indicates a reduced immune status. At the same time, their immune system is 
constantly activated to a state of slight inflammation, likely due to the continuous 
interaction of leukocytes with the foreign surface of the dialysis filters. In the last decades, 
several novel antibody drugs have been approved for the treatment of tumors, most of them 
of the IgG isotype. Major effects of these drugs in defense against tumor cells are mediated 
through indirect effector mechanisms such as ADCC. These indirect effector mechanisms 
depend not only on the target cell (tumor) and the antibody but also on the effector cell 
(leukocyte). It is yet unclear in which way regular hemodialysis influences the leukocytes 
ability to defend against tumor cells using antibodies. In this study, we investigated this with 
the mediation of antibodies. We used in vitro methods like 51Cr release assay or 
immunofluorescence to investigate the in vivo tumor defense and compared DP to healthy 
individuals (HI). We found an increased ability of DP’s peripheral blood mononuclear cells 
(PBMC) to kill EGFR coated tumor cells when ADCC was mediated by anti-EGFR antibodies of 
the IgG2 isotype. When ADCC was mediated by antibodies of the IgG1 isotype, DP and HI 
showed no significant difference. 
In order to examine whether the observed effect was restricted to ADCC or also occurred in 
antibody-dependent phagocytosis by cells such as PMN, we then strove to establish an assay 
using EGFR-coated microspheres. Principal conductibility and practicability of the chosen 
method could be demonstrated, and we determined optimal experimental conditions to 
maximize the observed phagocytosis effect. However, we were unable to show the 
antibody-dependency of phagocytosis, likely due to an alteration of the EGFR-molecule in 
the coupling procedure. 
To investigate further the effect of increased IgG2-mediated ADCC capacity in DP, we then 
experimented with subpopulations of leukocytes such as monocytes and NK-cells. In the 
heterogeneous PBMC population, we identified monocytes as the major faction contributing 
to the observed effect. An expression of FcγRII on the surface of NK-cells of DP or HI could be 
ruled out. 
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The proportion of monocytes from all PBMC was numerically raised in DP and their 
monocytes were shown to be more potent in ADCC, suggesting a heightened activation 
status. The activation of monocytes seems not to be due to changes in the FcR expression, as 
both DP and HI showed the same level of FcR expression, but seems to be due to an effect 
downstream the signaling-cascade. 
Our experiments indicate that cytotoxic effector cells of patients with end-stage renal 
disease undergoing dialysis are fully capable of antibody mediated tumor cell killing. We did 
not find any evidence that DP’s ability to perform ADCC is diminished compared to HI. 
Furthermore, our studies indicate that dialysis patients might profit particularly from certain 
therapeutic approaches which recruit monocytes as effector cells, such as IgG2 antibodies. 
Parts of this thesis were published in a paper called “Antibody dependent cellular 
cytotoxicity in patients on chronic hemodialysis” by Koch et al76, which appeared in the 
American Journal of Nephrology in 2013. 
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7 Zusammenfassung 
Patienten mit chronischer Niereninsuffizienz, welche sich regelmäßiger Hämodialyse 
unterziehen müssen (dialysis patients, DP), haben ein erhöhtes Risiko, solide Tumoren zu 
entwickeln, z.B. kolorektale Karzinome. Dies deutet auf einen reduzierten Immunschutz hin, 
während sich das Immunsystem von DP jedoch andererseits permanent im Zustand einer 
leichten Aktivierung befindet. Dies liegt u.a. an der Interaktion der Leukozyten mit den 
fremdartigen Oberflächen der Dialysefilter. In den letzten Jahren haben monoklonale 
Antikörper als Medikamente gegen Tumoren zunehmend an Bedeutung gewonnen, die 
meisten vom IgG-Isotyp. Antikörper wirken unter anderem über indirekte 
Effektormechanismen wie ADCC (antibody dependent cellular cytotoxicity, 
antikörpervermittelte zelluläre Zytotoxizität). Diese sind nicht nur von der Zielzelle 
(Tumorzelle) und dem Antikörper abhängig sondern auch vom Effektor (Leukozyt). Es ist 
noch unklar, auf welche Weise regelmäßige Hämodialyse die Fähigkeit von Leukozyten 
beeinflusst, mit Hilfe von Antikörpern Tumorzellen zu bekämpfen. Wir untersuchten dies 
indem wir DP mit gesunden Spendern (healthy individuals, HI) verglichen. In-vitro-Methoden 
wie 51Cr-release-assay oder Immunfluoreszenz wurden benutzt um die Tumorabwehr in vivo 
zu simulieren. Wir fanden eine erhöhte ADCC-Kapazität gegen EGFR exprimierende 
Tumorzellen in den mononukleären Zellen (PBMC) von DP, wenn anti-EGFR Antikörper vom 
IgG2 Isotyp wie panitumumab eingesetzt wurden. Bei IgG1- Antikörpern unterschied sich die 
ADCC-Kapazität bei DP und HI dagegen nicht.  
Um zu untersuchen, ob der beobachtete Effekt auf ADCC begrenzt war oder auch in 
Antikörper-vermittelter Phagozytose von Fresszellen wie z.B. Neutrophilen (PMN) eine Rolle 
spielt, begannen wir die Etablierung eines Assays auf Basis von Mikrosphären (beads) mit auf 
der Oberfläche fixierten EGFR-Molekülen. Die grundlegende Durchführbarkeit der Methode 
konnte gezeigt und optimale experimentelle Bedingungen definiert werden, doch es gelang 
uns nicht, die Abhängigkeit der Phagozytose von der Spezifität der IgG2 Antikörper zu zeigen.  
Um den Effekt der erhöhten IgG2-vermittelten ADCC-Kapazität in Hämodialysepatienten 
(DP) weiter zu untersuchen, betrachteten wir als nächstes verschiedene Untergruppen von 
Leukozyten, insbesondere Monozyten und NK-Zellen. Besonders Monozyten schienen an 
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dem beobachteten Effekt beteiligt, eine Expression von FcγRII auf der Oberfläche von NK-
Zellen in DP konnte als Ursache ausgeschlossen werden. 
Der Anteil von Monozyten an PBMC war bei Hämodialysepatienten signifikant erhöht, und 
die vorhandenen Monozyten zeigten eine erhöhte Lyserate im ADCC, was auf einen 
erhöhten Aktivierungsstatus hinweist. Diese Aktivierung scheint jedoch nicht auf einer 
Veränderung der FcR-Expression zu beruhen, sondern auf einen Effekt in einem 
intrazellulären Abschnitt der Signalkaskade. 
Unsere Experimente deuten darauf hin dass zytotoxische Effektorzellen von 
Dialysepatienten in der Lage sind Tumorzellen mit Hilfe von Antikörpern adäquat 
abzuwehren. Es ergaben sich keine Hinweise dass DP eine verminderte Fähigkeit zum ADCC 
gegenüber HI besitzen. Zudem deuten unsere Ergebnisse darauf hin, dass Dialysepatienten 
besonders von Therapieansätzen profitieren könnten, die mit Hilfe von IgG2- Antikörpern 
auf Monozyten als Effektorzellen beruhen. 
Teile dieser Doktorarbeit wurden unter dem Titel “Antibody dependent cellular cytotoxicity 
in patients on chronic hemodialysis” von Koch et al76 im „American Journal of Nephrology“ 
2013 publiziert. 
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8 Appendix 
8.1 Materials 
8.1.1 Chemicals 
Name Producer 
Ampicillin Roth 
APS ( =(NH4)2S2O8 =Ammonium persulfate) Sigma 
Bovine Serum Albumin Fraktion V Roth 
Bromphenolblue Sigma 
β-Mercaptoethanol Sigma 
Chromium51 Hartmann Analytik 
Destillied water Invitrogen 
Dimethylsulfoxid (DMSO) Sigma-Aldrich 
Ethanol  Roth 
Fetal calve serum (fetales Kälberserum) = 
(FCS) 
Invitrogen 
Glycerin Merck 
Hanks PAA 
Natriumazid Roth 
Natriumchlorid (NaCl) Roth 
Natriumhydroxid (NaOH) Roth 
Natriumdihydrogenphosphate (NaH2PO4) Roth 
Dinatriumhydrogenphosphate (Na2HPO4) Roth 
Penicillin/Streptomycin (Pen/Strep) PAA 
Percoll Biochrom, Berlin 
HCl Merck 
Sodium dodecyl sulfate (SDS) Sigma 
Tris Roth 
TritonX-100 Merck 
Trypanblau  Sigma-Aldrich 
Trypsin-EDTA (0,25%) Invitrogen 
Tween20 Merck 
1xPBS  PAA 
10xPBS  Invitrogen 
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Szintillationsflüssigkeit PerkinElmer 
o-Phenylenediamine dihydrochloride SIGMA-Aldrich, SIGMAFAST OPD P9187-50set 
SuperSignal Thermo Scientific 
TEMED (N,N,N,N-Tetramethylethylendiamin) Merck 
 
8.1.2 Solutions 
 Facs-buffer: PBS (PAA)  +1% BSA +0.1% sodium azide (Roth) 
 MACS-buffer: autoMACS rinsing solution, pH=7,2 (Miltenyi Biotec) 
 ELISA-washbuffer: PBS (PAA)  + 0.05% Tween20 (Merck) 
 TAE running buffer: 
 63% Percoll: 18.5ml hanks (PAA) + 31.5ml percoll (Biochrome) 
 70% Percoll: 15ml PBS (PAA) + 35ml percoll (Biochrome) 
 0.1 M Carbonate-buffer: 0.1 M Na2CO3 titrated to pH=9.6 with 0.1M NaHCO3 
 0.1 M MES-buffer: 19.2g 2-(N-Morpholino)ethansulfonsäure (MW 195.2) eluded in 
900ml distilled water. Titrated to pH=5.5 with 1M NaOH, then filled to 1000ml with 
distilled water. 
 0.2 M Borate-buffer: 0.2 M H3BO3 titrated to pH= 8.5 with 1 M NaOH. 
 BSA-Solution: 10mg/ml BSA (Roth) in 0.2M Borate-Buffer 
 Storage-buffer: 19ml 0.,1 M NaH2PO4-Monohydrate + 81ml Na2HPO4-Heptahydrate + 
1g BSA (Roth) + 5ml Glycerol (Merck) + 0.1g sodium azide (Roth) then filled up to 
1000ml with destilled water 
 FACS-buffer: PBS + 5g BSA (Roth) + 0.5ml sodium azide (Roth) 
 1.5M Tris-buffer: 181.7g Tris + 1 H20dest 
 Laemmli-buffer: 3.2ml 1M Tris-buffer + 3.5ml Glycerin + 1.5g SDS + 100mg 
bromphenolblue + 2.5ml β-Mercaptoethanol 
 R10+ medium: 500ml RPMI 1640 (PAA) +50ml (10%) FCS (Invitrogen), +5ml (1%) 
Penicillin/Streptomycin (PAA) 
 D10+ medium: 500ml DMEM (PAA) +50ml (10%) FCS (Invitrogen), +5ml (1%) 
Penicillin/Streptomycin (PAA) 
 
 
8.1.3 Cells 
Name Medium Producer 
A1207 D10+ DSMZ* 
A431 R10+ DSMZ* 
*Deutsche Sammlung von Mikroorganismen und Zellkulturen 
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8.1.4 Consumables 
Name Application Producer 
Serological Pipette Fluid handling Eppendorf 
Cell culture Flask Cell culture Falcon, Heidelberg 
Microtiter plates, 96 wells, V-
shape 
Flow cytometry Sarstedt 
Multiple Well Plate 96 wells, 
Round Bottom with Lid 
ADCC Sarstedt 
8-Well Streifen Nunc 
ImmunosorpTM Module 
ELISA Thermo Fisher Scientific, 
Roskilde, Dänemark 
96-Well Sample Plate Scintillation measurement Wallac, Turku, Finnland 
TopSeal-A Scintillation measurement PerkinElmer 
MACS LS Separation column Monocyte and NK-cell 
preparation 
Milteny Biotec 
Kodan Hautantiseptikum Anti septic spray Schülke 
Monovette-Kanüle  Sarstedt 
Soluble EGFR EGFR construct used for 
coupling 
Genmab, Utrecht 
MACS Pre-Separation Filter Cell strainer 30µm pores Miltenyi Biotec 
Fluoresbrite Carboxylate YG 1.0 
Micron Microspheres Cat#15702 
Beads Polysciences Inc. 
Fluoresbrite Plain YG 1.0 Micron 
Microspheres Cat#17154 
Beads Polysciences Inc. 
 
8.1.5 Machines 
Name Application Producer 
HeraSafe Lamina Heraeus Instrument, Hanau 
Coulter EPICS XL-MCL 
Durchflusszytometer 
Flow cytometry Beckman Coulter 
Heraeus Multifuge 3S+ Centrifuge Thermo Scientific 
Heraeus Megafuge 1.0R Centrifuge Thermo Scientific 
Orbitalschüttler Gyro Rocker 
SSL3 
Mixing of supernatant with 
scintillation fluid 
Stuart 
1450 LSC MicroBeta TriLux,  Scintillation-measuring PerkinElmer 
Tecan Sunrise Adsorbtion reader Groeding, Austria 
Pipetboy Pipetting aid Integra 
Neubauer-Zählkammer Counting chamber VWR 
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8.1.6 Antibodies 
Name Antigen (Target) Producer 
Polyglobin (Intratect) unspecific hIgG Bayer 
IgG-FITC polyclonal Beckman Coulter 
IgG-PE polyclonal Beckman Coulter 
IgG-ECD polyclonal Beckman Coulter 
IgG-PC-5 polyclonal Beckman Coulter 
IgG-PC-7 polyclonal Beckman Coulter 
CD3-ECD human CD3 Beckman Coulter 
CD14-ECD human CD14 Beckman Coulter 
CD16-ECD human CD16 Beckman Coulter 
CD19-PE human CD19 Beckman Coulter 
CD32-PE human CD32 Beckman Coulter 
CD45-FITC human CD45 Beckman Coulter 
CD56-PC-7 human CD56 Beckman Coulter 
CD89-PE human CD89 Beckman Coulter 
7AAD Viablity Dye --- Beckman Coulter 
cetuximab (Erbitux) human EGFR Merck 
panitumumab (Vectibix) human EGFR Amgen 
2F8T human EGFR Genmab 
225 IgA2 human EGFR Selfmade (Beyer JIM 2009) 
m425 human EGFR Merck 
OO5 human EGFR Genmab 
OO8 human EGFR Genmab 
O13 human EGFR Genmab 
hR3 human EGFR Nimotuzumab, TheraCim 
Rituximab (Mabthera) human CD20 Roche 
Trastuzumab (Herceptin) HER2/neu Roche 
KLH (Keyhole Limpet Hemocyanin) --- Genmab 
Unspezif. IgG1 --- Genmab 
Unspezif. IgG2 --- Genmab 
mTib92 --- ATCC 
mTH69 --- Selfmade (Gramatzki) 
mW6/32 human HLA-I ATCC 
m22 human CD64 (FcγRI) Genmab 
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mIV.3 human CD32 (FcγRII) Genmab 
m3G8 human CD16 (FcγRIII) Genmab 
mA77 human CD89 (FcαR) ATCC 
gαm-IgG-HRP murine Fc Dako 
gαm-FITC murine Fc Dako 
gαh IgG-PerCP human IgG Jackson ImmunoResearch 
Laboratories, Inc 
 
8.1.7 Kits 
Name Application Producer 
Qifikit FcR-Quantification Dako 
CD14 MicroBeads Monocyte purification 
(touched) 
Miltenyi Biotec 
Monocyte Isolation Kit II  Monocyte purification 
(untouched) 
Miltenyi Biotec 
NK Cell Isolation Kit  NK-cell purification 
(untouched) 
Miltenyi Biotec 
MycoAlert Mycoplasma detection Lonza AG 
 
 
8.1.8 Sample material (blood) 
 Written informed consent was obtained from all blood donors 
 exclusion criteria: infection, low Hb, taking of immune modulating drugs 
 
8.1.9 Software 
Name Application Producer 
GraphPad Prism 5 Analysis, statistics GraphPad Software, Inc  
OpenOffice, Word 2007 Writing Openoffice.org, Microsoft 
CXL Analysis of flow cytometry Beckman Coulter 
Endnote X4 Citations Thomson Reuters 
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